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PREDICTORS AND POTENTIAL MECHANISMS OF IMPROVEMENT IN ASTHMA CONTROL  
IN CHILDREN FOLLOWING ADENOTONSILLECTOMY. 
Maria B. Koenigs, Jonathan C. Levin, Lisa Gagnon, David E. Karas, and Geoffrey L. 
Chupp. Section of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal 
Medicine, Yale University School of Medicine, New Haven, CT.  
Recent small observational studies suggest that asthmatic children receive clinical benefit in 
asthma control following adenotonsillectomy (TA), but little is known about which clinical 
and biological characteristics impact improvement. We enrolled 213 children undergoing TA, 
including 136 children with asthma and 78 controls, in a longitudinal observational cohort 
study (YCAAD). An asthma questionnaire, Asthma Control Test (ACT) scores, and serum 
asthma biomarkers levels were obtained at baseline and at six-months. Interim analysis 
compared patient characteristics to a historical cohort (CT-Kids) of 49 children with asthma 
who underwent TA. Urgent care visits (P < 0.001), oral steroid courses (P < 0.001), and 
ACT scores (P < 0.001) all improved in children with asthma following TA. Serum Th2 
inflammatory markers, including IL-4 (P = 0.022) and IL-5 (P = 0.002), decreased following 
TA. Decreased IL-5 levels following surgery correlated with improvement in urgent care 
visits (P = 0.021), decreases in oral steroids (P = 0.02), and overall improvement in asthma 
control (P = 0.008). Children who were low or healthy weight, younger, female, had a 
history of sinusitis, and/or had a history of persistent asthma were more likely have 
improvement in their asthma following surgery. Elevations of serum IL-2, IL-4, IL-5, IL-13, 
IFN-γ, TNF-α, and GM-CSF levels were found in children whose asthma improved after TA.  
These clinical characteristics and biomarkers may help predict which children will receive 
maximum benefit in asthma control following TA.  
 
	   Koenigs et al. 2 
 
Acknowledgments 
Teamwork is an essential part of both science and medicine. This thesis simply would not 
have been possible without the help of my wonderful research team.   I would specifically 
like to thank: 
 
Dr. Geoffrey Chupp for being a superb mentor, for being my biggest advocate, and for 
showing me how a being an excellent scientist does not limit your ability to be a superior 
physician.  
 
Dr. David Karas, whose passion for pediatric otolaryngology has inspired me to become 
as amazing a surgeon as he is. 
 
Dr. Jonathan Levin, whose enthusiasm and hard work established the foundation of this 
research.  He is simply an impossible act to follow.  
 
Lisa Gagnon, whose friendship and dedication to this project made everything just go a 
little more smoothly. 
 
The members of the Chupp lab, who managed to laugh at my silly PowerPoint slides, 
led me on the correct path of scientific discovery, and helped with all of the technicalities 
of the lab.  
 
	   Koenigs et al. 3 
Dr. Eric Baum, Dr. Jennifer Setlur, Wendy Mackey, and Melissa Dziedzic for letting 
me invade their offices and ORs to recruit patients.  
 
Yale New Haven Hospital and North Haven Surgical Center OR staff for their 
patience and help in gathering data and samples.  
 
Vivek Kulkarni, who somehow found the time to both be a great friend and to teach me 
statistics over many a cup of coffee.  
 
My family and friends whose love and support got me through not only my thesis, but 
through all of medical school.  
 
And finally to the Richard K. Gershon, M.D. Student Research Fellowship and NIH-
NHLBI Medical Student Research Fellowship, without whose financial support this 
research would not have been possible.  
 
 
 
 
 
 
 
 
	   Koenigs et al. 4 
TABLE OF CONTENTS 
INTRODUCTION ......................................................................................................................................... 6 
THE ECONOMIC BURDEN OF ASTHMA IS SUBSTANTIAL ............................................................................... 6 
WHAT IS ASTHMA? ....................................................................................................................................... 7 
INFLAMMATION AND ASTHMA ...................................................................................................................... 8 
CLINICAL MANIFESTATIONS OF ASTHMA IN THE PEDIATRIC POPULATION .................................................. 9 
APPROACH TO THE MANAGEMENT OF ASTHMA IN CHILDREN .................................................................... 12 
BIOMARKERS IN ASTHMA CARE ................................................................................................................. 13 
BENEFITS AND LIMITATIONS OF PHARMACOLOGIC MANAGEMENT OF ASTHMA ........................................ 14 
MANAGEMENT OF ASTHMA BEYOND TARGETING THE LOWER AIRWAYS .................................................. 16 
ADENOTONSILLAR DISEASE IN CHILDREN .................................................................................................. 18 
ASTHMA AND ADENOTONSILLECTOMY ...................................................................................................... 19 
HYPOTHESES AND AIMS ....................................................................................................................... 21 
METHODS ................................................................................................................................................... 22 
YCAAD COHORT ....................................................................................................................................... 22 
YCAAD ENROLLMENT AND FOLLOW-UP .................................................................................................. 22 
CT-KIDS COHORT ...................................................................................................................................... 23 
WEIGHT DATA ............................................................................................................................................ 23 
SERUM SAMPLE COLLECTION AND PROCESSING ........................................................................................ 24 
CHITINASE ACTIVITY .................................................................................................................................. 24 
YKL-40 ELISA ASSAY ................................................................................................................................ 24 
BIO-PLEX ASSAY  ....................................................................................................................................... 25 
STATISTICAL ANALYSIS .............................................................................................................................. 26 
DEFINITION OF IMPROVEMENT IN ASTHMA CONTROL ................................................................................ 27 
RESULTS ..................................................................................................................................................... 28 
BASELINE DEMOGRAPHICS YCAAD COHORT ........................................................................................... 28 
IMPROVEMENT IN ASTHMA CONTROL FOLLOWING ADENOTONSILLECTOMY ............................................. 28 
CIRCULATING INFLAMMATORY MARKERS AFTER TA ................................................................................ 29 
EFFECT OF WEIGHT ON IMPROVEMENT IN ASTHMA CONTROL FOLLOWING TA ........................................ 29 
Baseline demographics CT Kids Cohort ............................................................................................... 30 
Baseline demographics interim CT Kids Cohort ................................................................................... 30 
Baseline Asthma Control ....................................................................................................................... 30 
Post-operative Asthma Medication Use ................................................................................................ 31 
Asthma Control and Healthcare Utilization .......................................................................................... 31 
CLINICAL AND BIOMARKER CHARACTERISTICS THAT MAY IMPACT IMPROVEMENT IN ASTHMA CONTROL 
FOLLOWING TA .......................................................................................................................................... 32 
Minimally Clinically Indicated Difference in ACT and TRACK Score ................................................. 32 
Improvement in Urgent Care Visits ....................................................................................................... 33 
Improvement in Oral Steroid Courses ................................................................................................... 33 
Composite Variable Improvement ......................................................................................................... 34 
DISCUSSION ............................................................................................................................................... 36 
BASELINE COHORT DEMOGRAPHICS .......................................................................................................... 36 
ASTHMA IMPROVES FOLLOWING TA .......................................................................................................... 37 
BIOMARKERS OF TH2 ASSOCIATED ASTHMATIC INFLAMMATION IMPROVE FOLLOWING TA ..................... 38 
CLINICAL CHARACTERISTICS THAT MAY PREDICT IMPROVEMENT IN ASTHMA FOLLOWING SURGERY ..... 42 
Children who are overweight receive less benefit from TA for asthma control .................................... 42 
Asthma control in younger children is more likely to improve following TA ........................................ 42 
Asthma control is more likely to improve in girls than boys following TA ........................................... 46 
Children with baseline sinusitis have decreased urgent care visits and steroid courses after TA ........ 47 
Children with persistent asthma have improvement in asthma control following TA ........................... 48 
	   Koenigs et al. 5 
INFLAMMATORY ASTHMA BIOMARKERS ARE ELEVATED IN CHILDREN WHOSE ASTHMA IMPROVES 
FOLLOWING TA .......................................................................................................................................... 49 
Children whose asthma improves following TA have elevations of Th2 cytokines prior to TA ............ 49 
Non-Th2 inflammatory cytokines are elevated in asthmatics whose asthma improve after surgery .... 50 
STUDY STRENGTHS AND LIMITATIONS ....................................................................................................... 52 
CONCLUSIONS AND FUTURE DIRECTIONS ..................................................................................... 53 
TABLES ........................................................................................................................................................ 54 
TABLE 1. BASELINE DEMOGRAPHICS OF THE YCAAD COHORT ................................................................ 54 
TABLE 2.  ASTHMA BIOMARKERS IN RESPONSE TO TA .............................................................................. 55 
TABLE 3A. BASELINE DEMOGRAPHICS INTERIM YCAAD COHORT AND CT-KIDS COHORT. ..................... 55 
TABLE 3B. BASELINE ASTHMA CONTROL AND HEALTHCARE UTILIZATION OF INTERIM YCAAD COHORT 
AND CT-KIDS  
 ................................................................................................................................................................... 56 
TABLE 3C.  POST-OPERATIVE CHANGE MEDICATION USAGE AND HEALTHCARE UTILIZATION IN THE CT 
KIDS COHORT ............................................................................................................................................. 56 
TABLE 3D.  POST-OPERATIVE CHANGE MEDICATION USAGE AND HEALTHCARE UTILIZATION IN THE 
YCAAD COHORT ....................................................................................................................................... 57 
TABLE 4. BASELINE CHARACTERISTICS THAT INFLUENCE IF CHILD HAS CLINICALLY SIGNIFICANT 
IMPROVEMENT IN ACT/TRACK SCORE ..................................................................................................... 58 
TABLE 5. BASELINE CHARACTERISTICS THAT INFLUENCE IF CHILD HAS IMPROVEMENT IN URGENT CARE 
VISITS FOLLOWING SURGERY. ..................................................................................................................... 59 
TABLE 6. BASELINE CHARACTERISTICS THAT INFLUENCE IF CHILD HAS CLINICALLY SIGNIFICANT 
IMPROVEMENT IN STEROID COURSES. ......................................................................................................... 60 
TABLE 7. BASELINE CHARACTERISTICS THAT INFLUENCE IF CHILD HAS CLINICALLY SIGNIFICANT 
IMPROVEMENT IN COMPOSITE IMPROVEMENT ............................................................................................. 61 
FIGURES ...................................................................................................................................................... 62 
FIGURE 1. CHILDREN’S ASTHMA IMPROVES FOLLOWING TA ...................................................................... 62 
FIGURE 2. SERUM BIOMARKER LEVELS DIFFEREN IN CHILDREN WITH AND WITHOUT ASTHMA ................... 62 
FIGURE 3. TH2 CYTOKINES DECREASE IN CHILDREN WITH ASTHMA FOLLOWING TA. ................................ 63 
FIGURE 4. IMPROVEMENT IN ASTHMA CORRELATES WITH DECREASES IN IL-5 .......................................... 63 
REFERENCES ............................................................................................................................................. 64 
 
 
 
 
 
 
 
 
 
	   Koenigs et al. 6 
INTRODUCTION 
Asthma is a common inflammatory disease of the lower airways with significant 
morbidity and mortality worldwide. There is a growing understanding that the 
pathophysiologic processes that contribute to asthmatic inflammation exist beyond the 
lower airway. Recent work has demonstrated that upper airway disease, including 
adenotonsillar disease in children, may worsen asthma control. [1, 2] Despite the 
prevalence of adenotonsillar disease in childhood, there has only been limited 
investigation on the impact of adenotonsillectomy (TA) on asthma control.   
The Economic Burden of Asthma is Substantial 
Asthma is one of the most common chronic morbidities in children in Western 
countries. In the United States approximately 14% of children are diagnosed with asthma 
during their lifetime and 9.6% of children carry a current diagnosis of asthma. [3] Over 
300 billion people worldwide of all ages carry a diagnosis of asthma [4] with a significant 
of proportion of disease in the pediatric population. There is increasing recognition that 
asthma is a global disease, with a significant increase in disease prevalence in Latin 
America, Northern Europe, Eastern Europe, and Africa. Over a five to ten year period in 
the International Study of Asthma and Allergies in Childhood (ISAAC)—a large 
multicountry cross sectional-survey of over 50 countries—there was increasing global 
prevalence of asthma of 0.13% per year worldwide. [5] Although high-income countries 
have higher prevalence rates of asthma in childhood, severe disease is more common in 
less affluent countries. [6] With the increasing prevalance of asthma worldwide and 
increasing recognition of impact disease in the less affleunt countries, the economic 
burden of disease will continue to expand unless better disease interventions are found.  
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The current economic burden of asthma is substantial. The treatment of asthma 
alone accounts for eight billion dollars of US health care expenditure annually [7], with 
$3,856 spent per asthmatic per year. [8]  In 2004 in the United States it was estimated that 
pediatric asthma was accountable for 12.8 million missed school days, 750,000 
emergency room visits, 198,000 hospitalizations, and 186 childhood deaths. [6] As the 
prevalence of asthma only continues to increase, having interventions that improve and 
modulate asthma control are necessary to reduce disease burden. 
What is asthma?  
Asthma is an inflammatory disease of the lower airways that results in 
intermittent airway obstruction as evidenced by increased airway hyperreactivity; 
symptoms of dyspnea, wheezing, shortness of breath; and/or nocturnal coughing. [9, 10] 
A major in challenge both the diagnosis and treatment of asthma is that is a 
heterogeneous disease; the natural history of disease varies largely between individuals 
and depends on factors such as age of first symptoms onset, overall disease severity, and 
the patient’s sex. [1, 11]  
Although descriptions of asthma exacerbations date back to the second century 
A.D.[12], the exact etiology of asthma remains unclear. It is hypothesized that asthma 
occurs as a combination of both early environmental exposures and underlying genetic 
and biological susceptibility. [9] Over one hundred gene loci are associated with asthma 
including genes candidates that are part of inflammatory pathways (e.g. IL-4 cluster on 
chromosome 5), remodeling (e.g. ADAM33), and medication response (beta-adrenergic 
receptor mutations). But genetic susceptibility alone fails to fully explain the clinical 
spectrum of disease. Early infantile and prenatal exposures, such as early childhood viral 
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bronchiolitis, allergen exposure, secondhand smoke exposure, and pollutants exposure, 
also contribute to childhood risk of asthma. As such, the exact nature of the interaction 
between the biologic susceptibility and environmental exposures is poorly understood 
and currently an active area of research. For example, although it has been described that 
early childhood bronchiolitis with wheezing in infants is a risk factor for development of 
asthma, the majority of children with early respiratory virus associated wheezing do not 
develop asthma [13]. Recent work with the COAST birth cohort demonstrated that 
children with a homozygous gene mutation in the 17q21 locus who had an episode of 
rhinovirus-associated wheezing as an infant had an increased risk (OR=26.1) of 
developing asthma compared to children without this genetic susceptibility. [14] 
Connecting underlying genetic susceptibility with environmental triggers may be 
essential in helping to understand the pathophysiologic processes that drive development 
in asthma and to help with management of disease.  
Inflammation and asthma  
Although the exact etiology of asthma remains to be elucidated, there is strong 
evidence that inflammation of the lower airways drives the airway hyperresponsiveness 
that is responsible for the intermittent wheezing and shortness of breath that characterizes 
asthma. [15] In allergic asthma—the most common form of asthmatic inflammation 
found in children (See Clinical Manifestations of Asthma in the Pediatric Population)—
the walls of the lower airways are infiltrated with mononuclear (primarily CD4+ T-helper 
cells) and eosinophils, although other proinflammatory cells such as mast cells, 
macrophages and neutrophils are also in abundance.  T-helper cells Type II (Th2) are 
thought to both initiate and perpetuate asthmatic inflammation by priming the allergic 
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airway and increasing antigen-induced allergic inflammation. [16] After initial 
sensitization of the airway to aeroallergen, Th2 cells upregulate inflammation through the 
expression of cytokines including IL-4, IL-5, and IL-13 that promote inflammatory cell 
recruitment and perpetuate of the allergic response. This inflammation is further 
worsened through increased expression of other proinflammatory molecules such as 
TGF-beta, GM-CSF, and MMP may also trigger airway remodeling, with increase in 
respiratory smooth muscle mass that is also associated with airway hyperresponsiveness. 
[17] 
One of the challenges with characterizing the exact immune response in pediatric 
asthma specifically is that it is a clinically heterogeneous disease that affects children 
differently depending on age of onset and disease severity. Therefore, it is reasonable that 
the underlying biochemical and physiologic basis of disease could differ between 
different phenotypes of asthma. In asthmatic mouse models there are a significant 
pathologic differences found sensitized infantile mice compared with juvenile and adult 
mice. [18] Hypersensitized infantile mice developed goblet cell hypertrophy compared to 
juvenile mice who were more likely to develop airway smooth muscle hypertrophy and 
have increased IL-5 expression, suggesting a fundamental pathological difference 
between asthma development based on age of symptom onset. Therefore, the exact 
pathophysiology of asthmatic inflammation may vary based on asthmatic phenotype.  
Clinical Manifestations of Asthma in the Pediatric Population  
The heterogeneity of asthma makes it a challenging disease to both diagnose and 
treat. There is a growing interest to classify asthmatic phenotypes to better predict natural 
history of disease, to connect clinical outcomes with underlying pathophysiologic 
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differences, and to individualize treatment regimens. The heterogeneity of clinical course 
of asthma and early childhood wheezing is evident even in the pediatric population 
making both diagnosis and management of the disease challenging. A major goal in 
pediatric asthma care is to improve in early identification of asthma subtypes that might 
improvement long-term management of disease.  
Pediatric asthma is frequently classified into three major phenotypes: 1) early 
onset allergic, 2) exercise-induced, and 3) obesity-related disease. [19] Early onset 
allergic onset asthma covers a full range of severity and is often associated with allergy, 
atopy and rhinitis. On a molecular level this phenotype is connect with increased serum 
IgE, elevation of Th2 cytokines, and potentially related to 17q12 gene mutations. In 
contrast, exercised induced asthma in children tends to be mild, intermittent, and airway 
hyperreactivity related to mast-cell activation, intermittent Th2 cytokine spikes, and 
cysteinyl leukotrienes. A third major clinical asthma phenotype in children, primarily 
found in adolescent females, is an obesity-associated phenotype. Obesity-associated 
asthma may be a distinct pathophysiologic entity from general childhood allergic asthma 
characterized by increased Th1 inflammation and a non-atopic phenotype. [20-23] 
Although these clinical phenotypes have been described, often clinical characteristics are 
not easily evident in early childhood, making it challenging to predict long-term 
pulmonary outcomes.  
Another major challenge in the diagnosis of asthma in childhood is that wheezing 
is common in children under the age of three; up to thirty-three percent of all children 
have wheezing prior to this age but only 40% of that population goes on to develop 
persistence of disease. [13] Martinez et al. in a birth cohort of 1,246 infants in Tucson, 
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AZ identified three major phenotypes of childhood asthma: 1) early onset intermittent 
wheezing, 2) early onset persistent wheezing, and 3) late onset wheezing (where age of 
onset is demarcated by the being less or earlier than age three). [13] These wheezing 
phenotypes correlated with long-term response to treatment and lung function. Using 
patient characteristics associated with wheezing the Tucson group developed an “Asthma 
Prediction Index” where if an infant with greater than or equal to four wheezing episodes 
neither met one major criteria (parental history of asthma or physician diagnosis of atopic 
dermatitis) or two minor criteria (physician diagnosed allergic rhinitis, wheezing 
unrelated with colds, or blood eosinophilia) they had a NPV of 91.6% for developing 
asthma by 6 years of age. [24] Despite the importance of clinical prediction of disease, 
the Tucson classification does not explain on a molecular basis the variation in asthma 
phenotypes nor aide in clinical  decision-making. 
Interestingly, despite the specific characteristics underlying the aforementioned 
classification strategies, there has been less success in connecting these clinical 
characteristics with specific inflammatory markers that predict long-term outcomes and 
explain biological differences between phenotypes. Because of concern for bias in the 
phenotypic classification of asthma, there has been increasing interest in using unbiased 
approaches in classification schemes. Especially as the majority children have relatively 
normal lung function during symptom free periods, even with clinically severe asthma, 
there is a need to identify high-risk individuals to better target interventions. In the 
Severe Asthma Research Program (SARP) in school-aged children, four phenotypes of 
pediatric asthma were identified using an unbiased cluster analysis: 1) late onset 
symptomatic asthma with normal lung function 2) early onset atopic asthma with normal 
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lung function 3) early onset atopic asthma with mild airflow limitation 4) early onset 
atopic asthma with advanced airflow limitation. [25] These phenotypes correspond 
directly with asthma duration, number of asthma medication, baseline FEV1 and 
potentially with the biomarker eNO. This understanding of these phenotypes may 
eventually help practitioners to better target disease and to be able to educate parents on a 
child’s course of disease. 
Alternatively, Woodruff et al used a genome-wide profiling of airway epithelial 
cells of moderate and found two major phenotypes of asthma: Th2 high (associated with 
the regulatory genes for IL-4, IL-13, and IL-5 expression) and Th2 low. [26] 
Interestingly, the Th2 high group airway hyperesponsiveness had a much-improved 
response to corticosteroids compared to the Th2 low phenotype [27], suggesting that a 
better understanding molecular characteristics of disease may help clinicians guide 
treatment in a more directed fashion. 
Approach to the management of asthma in children 
The main goal of asthma care is to control symptoms with minimal medical 
intervention. Asthma control is defined by the degree to which symptoms, functional 
impairment, risk of adverse events is minimized by treatment. [9] Asthma control in 
children is monitored by patient description of symptoms of breathlessness, interference 
with normal activity, and nighttime/early daytime awakenings.  Validated questionnaires 
of asthma control, such as the Asthma Control Test (ACT), the Childhood Asthma 
Control Test (c-ACT) and Test for Respiratory and Asthma Control (TRACK) are 
particularly useful in both clinical practice and in research as they both evaluate a 
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patient’s control over a defined period of time and have well-defined clinical thresholds 
for changing medical management. [28-30]  
A major challenge in asthma care is the limitation in available objective data that 
guides diagnosis and management of disease. Pulmonary function tests are the 
cornerstone of objective testing in both diagnosis and treatment in asthma in both 
pediatric and adult patients. Although FEV1 in the presence or absence of bronchodilator 
response helps clinicians to diagnose and manage of disease, most children under the age 
of six cannot reliably perform the full exhalation needed for testing.  As 80% of children 
have symptom onset by one year of age [9, 12], there is a need for more reliable testing in 
children of younger age groups.  Because of the limitations of PFTs in younger children, 
there has been growing interest in the role of biomarkers to diagnose, monitor control, 
and evaluate treatment response of asthma in young children (see Asthma Biomarkers 
Section).  
Biomarkers in Asthma Care 
NIH criteria defines a biomarker as a measurable substance that characterizes a 
biologic, physiologic or pathologic response to either a therapeutic treatment or disease 
management [15]. In asthma care there has been limited success in finding readily 
available biomarkers of that correlate with clinical disease outcomes.  Exhaled nitric 
oxide (eNO) is considered to be a marker of allergic inflammation in the lower airways 
and may be a useful biomarker for allergic asthma in younger children, as it testing for it 
is non-invasive, inexpensive, and can be reliably done in young children. Although 
elevations of eNO correlate with asthma diagnosis and have a dose dependent decrease 
after treatment with ICS, its clinical utility remains uncertain, especially as the marker is 
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also elevated in atopic children without asthma. [9] Th2 associated cytokines, such as IL-
4, IL-5, and IL-13 have been to found to be elevated in the serum, bronchoalveolar lavage 
fluid (BALF) and the sputum of children with asthma. But as cytokines have a large 
variable range across the population, they have limited utility as a strict predictive 
biomarker of disease activity. Despite this limitation, changes in cytokine levels 
following treatment strategy may connect a biological response to a clinical intervention. 
[15, 31]  
Another potential family of asthma biomarkers is the chitinase and chitinase-like 
proteins. Chitinases are evolutionarily conserved enzymes that degrade chitin, a complex 
polysaccharide found in insect and fungal debris that triggers host inflammation. In 
children, elevated chitotriosidase—the primary active chitinase of the lung—has been 
associated with clinical asthma severity. [32] The chitinase-like protein YKL-40, which 
binds and sequesters chitin, has been found to be elevated in the serum of asthmatics and 
correlates with disease severity. [33, 34] In children elevation of YKL-40 has been 
correlated with treatment resistant disease and asthma severity. [35] Therefore, chitinase 
and chitinase-like proteins may be important surrogate biomarkers that aid in the 
management of pediatric asthma.  
Benefits and Limitations of Pharmacologic Management of Asthma Symptoms 
Pharmacologic treatment of asthma focuses on both alleviating acute respiratory 
symptoms and improving chronic airway hyperresponsiveness. The long-term goal of 
management is to relieve both short-term impairment (e.g. shortness of breath, nocturnal 
cough) and to minimize risk of adverse events (e.g. intubation, death). Therefore, the 
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treatment strategy is two-fold: short term agents that help in acute exacerbation of airway 
responsiveness and long-term anti-inflammatory agents.  
For short-term airway hyperresponsiveness, the cornerstone of management is the 
use of short acting beta-agonists such as albuterol. The goal of short acting beta-agonist 
use is to aid in improvement symptoms of airway hyperreactivity and prevent anticipated 
bronchospasm prior to exercise (specifically for patients with exercise sensitivity).  For 
acute exacerbations, systemic corticosteroids may be required and are rarely required for 
long-term control of severe asthma in children. Although excellent at reducing 
inflammation and acute symptoms, the long-term consequences of systemic 
corticosteroid use are profound—including metabolic effects, growth suppression, 
osteoporosis, and cataract formation[9]. Therefore, a major goal in pediatric asthma care 
is to limit a child’s exposure to oral corticosteroids by decreasing acute exacerbations.  
Adequate treatment of persistent asthma with preventative asthma medication has 
shown to both decrease asthma morbidity and to improve asthma control. [36] The 
general approach taken to asthma pharmacotherapy in persistent asthmatics is a “step up, 
step down management plan” in which patients are placed on a medication regimen that 
completely controls symptoms and with a decrease in symptoms medications are tapered 
off.  For persistent asthma, inhaled corticosteroids (ICS) are the preferred first-line 
therapy as they both improve lung function and asthma control. Although they aid in 
improving asthma, ICS do not alter the natural history of disease [9] and have significant 
adverse side effects including oral candidiasis and vocal dysphonia. In children, concern 
has also been raised that long-term use of ICS may result in growth suppression and 
osteoporosis; in the CAMP cohort—a large cohort of 1041 children being treated with 
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either with daily ICS or daily inhaled non-ICS—there was a 1.7 cm decrease in height of 
girls being treated with chronic ICS. [9, 37] Alternative agents to aid in improving 
asthma control include leukotriene receptor antagonists, cromones, and theophylline, 
although generally these medications are added as additional therapy in patients who do 
not respond to ICS compared to primary therapy. There is increasing interest in the use of 
long-acting beta-agonists in the support of moderate persistent asthma in children who 
suffer from nocturnal symptoms [38], although concern has been raised for worsening of 
status asthmaticus in children [9]. Although general incidence of preventative asthma 
medication use has doubled since 1988 [36], there is still a need for improved treatment 
adherence and optimization of management of disease beyond conventional treatment.  
Management of Asthma Beyond Targeting the Lower Airway  
Because of the impact that environmental exposures have on asthma, there is 
interest in expanding the treatment of asthma beyond targeting the lower airways. 
Although home environmental interventions (such as avoidance of allergens and second-
hand smoke) have been a mainstay in pediatric asthma education, there is growing 
evidence that avoidance of allergens in early life may alter the natural course of disease. 
As allergy and asthma are frequently co-morbid, prevention of early life exposure to 
allergens associated with worse asthma control in high-risk children may impact 
development of disease. In Canada, in a high-risk cohort of 308 asthmatic children, in 
children who underwent early preventative measures to avoid allergen exposure and were 
breast fed there was a decreased prevalence (12.9%) of asthma compared to children 
without these measure in place (prevalence 25%) at seven years of age. [39] Similar 
studies in the Netherlands[40] and in the Isle of Wight[41] have shown consistent results 
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of decreasing asthma symptom development by decreasing early childhood allergen 
exposure. But greater sample size, follow-up time, and stratification of patient 
characterizes are needed to asses if the intervention does impact natural history of 
disease.[42] 
There is also a growing understanding there is an interaction between chronic 
upper airway inflammation and worsening of asthma control, which is often termed the 
“One Airway Hypothesis.” For example, rhinitis is a common co-morbidity with asthma, 
especially in the pediatric population. Approximately 90% of children with asthma have 
rhinitis[2] and up to 60-78% of children with asthma have allergic rhinitis. [43] Chronic 
rhinitis may worsen asthma by limiting the humidification and warming that nasal 
berathing normally provides and by filtering of allergens from environment.[2] 
Improvement in allergic rhinitis improves inflammation in the lower airways, asthma 
symptoms, and decreases asthma medication use. [9] Treatment of allergic rhinitis, 
including nasal steroids and anti-histamines is now considered a peripheral treatment for 
asthma. [2, 9, 44] 
Adenotonsillar disease is a common form of upper airway disease in children with 
as many as 2-3% of children in the general population having sufficient adenotonsillar 
hypertrophy to cause polysomnographic evidence of obstructive sleep apnea.[45] In 
severe and moderate asthmatic children, there is a higher prevalence of obstructive sleep 
apnea compared to a general pediatric population. [46] Ross et al described in a cohort of 
108 asthmatic children that individuals with sleep disordered breathing had a 5.02 OR of 
developing severe asthma over a one year period. [46] Despite the prevalence of 
adenotonsillar disease in childhood [47], there has been limited investigation of how 
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surgical management of adenotonsillar disease may impact asthma control (See Asthma 
and Adenotonsillectomy).  
Adenotonsillar Disease in Children 
The adenoids and tonsils are the largest accumulation of lymphoid tissues in 
Weldeyer’s ring, the collection lymphoid tissue along the upper edge of pharynx.  
Dominated by B-cells, they are of thought to play a role in primary antigen surveillance 
of the upper airway and immunoglobulin production. [48, 49] The immune role of the 
adenoids and tonsils is most profund in children, as they involute in both size and activity 
during puberty.  
Adentonsillectomy (TA) is one of the oldest described surgeries, with the first 
operation being performed in 10 A.D. by the Greek Physician Celsus. [49] In 2006, 
530,000 adenotonsillectomies (TAs) were performed in the US alone and accounted for 
16% of all ambulatory surgery in children. [48, 50] The two most common indications for 
tonsillectomy are recurrent infection (i.e. recurrent tonsillitis, recurrent adenoiditis, 
peritonsillar abscess) and for sleep disordered breathing. [47, 48]  Sleep disordered 
breathing (SDB) represents a spectrum of upper airway disease that ranges from primary 
snoring to obstructive sleep apnea (OSA). Obstructive sleep apnea in children is defined 
at least one obstructive apneic episode or evidence of obstructive hypoventilation during 
nocturnal polysomnography. [51] Unlike in adults, adenotonsillar hypertrophy is a major 
contributor to dynamic airway obstruction in children, especially as the adenoid to airway 
ratio is largest in early childhood. [52] Airway narrowing in children with OSA occurs 
along the upper two-thirds of the airway and the maximal obstruction is where the tonsils 
overlap the adenoid tissue. [53] Concern has been raised about long-term complications 
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arising from chronic OSA in children—including worse neurocognitive outcomes, 
cardiovascular strain, and poor behavior—and now SDB is the most common indication 
for TA.   
Although there still remains debate on the absolute indications for TA and timing 
of surgery [48, 54, 55], many children receive significant benefit from surgery in 
decreasing upper airway obstruction, decreasing incidence of infection, improving overall 
health and quality of life. [55] The current recommendation for TA in children with 
recurrent tonsillitis (RT) follows the Paradise Criteria: removal is indicated if a child has 
seven episodes of RT in one year, five in two consecutive years, or three in three 
consecutive years. For children with SDB, if SBD is accompanied by growth retardation, 
poor school performance, behavioral problems, and enuresis, TA should be considered. 
[55] For children with less clear symptoms of SDB but with a nocturnal PSG consistent 
with OSA, TA is indicated.  
Asthma and Adenotonsillectomy 
Despite the prevalence of adenotonsillar disease in childhood, there has been 
limited investigation of how surgical management of adenotonsillar disease may impact 
asthma control.  In several small retrospective cohort studies, researchers observed that 
patient-reported asthma control improved following TA, with a decrease in use of 
asthma-related medications, a decrease healthcare utilization and an increase in Asthma 
Control Test (ACT) scores. [56-59] In the Childhood Adenotonsillectomy Trial (CHAT), 
a large cohort of 454 children undergoing either immediate adenotonsillectomy or 
tonsillectomy delayed for three months, it was noted that there were only three asthma 
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exacerbations for children receiving early adenotonsillectomy compared with 18 
exacerbations in the watchful waiting arm, including three serious adverse events. [54] 
Kheirandish-Gozal et al. found in cohort of 35 children with asthma and OSA 
after undergoing TA they had improvement in number of oral steroid courses, decrease in 
asthma symptom scores, and decrease in beta-agonist use. [58] Previous work in our lab, 
demonstrated in a cohort of sixty children with asthma undergoing TA [1, 60] that 
children with asthma had robust post-operative improvement in asthma control and 
decreased healthcare utilization after surgery.  In addition to improvement in clinical 
asthma control, it was also found that chitinase activity—which reflects serum 
chitotriosidase activity—decreased following surgery selectively in asthmatic children 
and was elevated prior to surgery in children whose asthma improved following surgery 
suggesting that baseline chitinase may be useful in predicting which children’s asthma 
will improve following surgery. [60] In addition to changes in chitinase expression, we 
found that in a limited sample of whole blood mRNA microarrays that the plasmin 
activation inhibitor SERPIN B2, a genomic signature that has previously been associated 
with asthma and related to IL-13 expression [26], may also decrease in asthmatic children 
with improvement in symptoms following surgery [1]. These findings suggest that 
mediators of asthmatic inflammation may decrease in children undergoing 
adenotonsillectomy and may play a role in explaining post-operative improvement in 
asthma.  
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HYPOTHESES AND AIMS 
Despite a growing understanding of the impact that TA has on improving asthma 
control, there still has been only limited investigation on specific clinical and biological 
characteristics that influence which children have improvement in their asthma following 
surgery. We hypothesized that we could identify both patient characteristics and 
molecular signatures that correlate with post-operative improvement in asthma control. 
We postulate that molecular signatures related to asthmatic inflammation will change 
following TA and that these changes in molecular signature will correlate to 
improvement in asthma.  
Specific Aims of the Study 
I. To expand the established cohort of pediatric patients, both children with and without 
asthma who undergo TA for reasons other than asthma control.   
II. Determine clinical asthma response following TA with a focus on change in ACT 
score and patient reported outcomes.  
III. To investigate biochemical alterations following TA using proteomic analysis in 
order to better understand the changes in systemic inflammation that drive 
improvement in asthma symptomatology post-operatively. 
IV. To identify clinical and biological characteristics that correlate with improvement 
after surgery. 
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METHODS 
YCAAD cohorta 
Over a 25-month enrollment period (December 2011-February 2013), as part of 
currently ongoing trial, children ages 2-18 who were undergoing TA for standard 
indications were enrolled at Yale New Haven Children’s Hospital or at the North Haven 
Surgical Center. This study was approved by the Yale IRB; parental consent and child 
assent (if older than age 7) were obtained prior to enrollment in study.  
YCAAD Enrollment and Follow-Up  
As previously described [60] parents completed an asthma questionnaire and 
either age-appropriate ACT (ACT or c-ACT) or TRACK score on the day of surgery. A 
child was classified as asthmatic if a primary care provider, allergist, or pulmonologist 
had diagnosed the child with asthma prior to enrollment in the study. The questionnaire 
included an extensive pulmonary history (including age of onset of asthma symptoms, 
asthma triggers, current asthma medication use, urgent care visits, and oral steroid 
courses), presence of asthma-associated comorbidities (including sinus disease, allergy, 
atopy, and GERD) and demographic data. Race and Ethnicity data were self-reported 
according to the guidelines of the US Census. TRACK and c-ACT scores were rescaled 
to a 25 scale to be compared with the teen ACT score as described previously. [60] 
Intraoperatively, with the help of the anesthesia team, serum serum blood samples were 
obtained.   
Six months following surgery, patients were contacted for follow-up visit either 
by telephone or email. A modified questionnaire was completed either over the phone or 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  a	  This thesis is a continuation of the work started by Jonathan Levin, MD. Subjects were enrolled by Lisa 
Gagnon, APRN, Jonathan Levin, MD, or this author. Chitinase assays were either performed by Jonathan 
Levin or this author.  
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at a clinical site visit. Venous sampling was additionally offered to children at the follow-
up visit, and children who agreed to participate received compensation. Incidence of 
clinical events, were rate-adjusted to a standardized twelve-month period as described 
previously[60].  
CT Kids Cohortb 
Asthmatic children ages 2-18 who were undergoing TA for standard indications 
were enrolled over a 24-month period from 2008-2010. All children included in the study 
had previous clinician diagnosis of asthma. This study was independently approved by 
the Yale IRB; parental consent and child assent (if older than age 7) were obtained prior 
to enrollment in study.  
Parents completed an asthma questionnaire prior to the day of surgery that 
included healthcare utilization over the last year (number of emergency room visits and 
pediatrician visits), socioeconomic burden of disease (missed school days and missed 
work days), asthma medication use, asthma phenotype, and other co-morbidities 
(sinusitis, GERD, atopy). One-year following surgery parents were contacted for follow-
up, at which time the baseline asthma questionnaire was repeated. 
Weight Data (Both CT Kids and YCAAD) 
Pre-operative height and weight were obtained either by nursing staff on the day 
of surgery or from communication with the parents about their child’s measured height 
and weight within six months of the surgical date. Each child’s body mass index (BMI) 
and age appropriate BMI percentile was calculated using the Center for Disease Control 
and Prevention BMI calculator. [61] Children were classified as overweight if their BMI 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
b CT-Kids Cohort data was collected by Lisa Gagnon, APRN. All statistics run on this patient population were 
performed by the primary author of this study.  
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was greater than the 85th percentile or low/healthy weight (LHW) if their BMI was less 
than the 85th percentile. For the YCAAD Cohort, parents were asked on the day of 
surgery about their perception of child’s weight as Low Weight, Normal, Overweight, or 
Obese. For children with available BMI data, the BMI data was compared with parent’s 
reported weight perception. If the child BMI did not correlate with parent’s description, 
they were re-categorized based on BMI. Children were then clustered into LHW or 
Overweight groups to form the composite variable of parent-adjusted weight (PAW). 
Serum Sample Collection and Processing (YCAAD Only) 
Serum was isolated by centrifugation of whole blood 405 xg for 10 minutes to 
separate RBC from serum immediately after collection. The samples were stored at either 
-20°C or -80°C until biological assays were performed.  
Chitinase activity 
Chitinase activity was determined using a standard fluorometric assay described 
previously. [60, 62] Briefly, 20 µL of serum was added to 180µL of 22 µMol solution of 
4-methylumbelliferyl-β-D-N,N’,N’’-triacetylchiotrioside in McIlvain Buffer. The 
reaction was incubated at 37°C for 30 minutes after which enzymatic reaction was 
terminated with the addition of 2 mL of 0.3 M glycine-NaOH, pH 10.6. Samples were 
excited at 365 nm and emission was measured at 445 nM using a Sequoia Turner 
fluorometer. Enzymatic activity was calculated in nM/mL*h using a standard curve of 4-
methylumbelliferone.  
YKL-40 ELISA Assay 
Serum YKL-40 levels were determined by ELISA per manufacturer’s protocol 
(Quidel, San Diego, CA). In brief, 20 µL of serum or standards were added to 
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streptavidin ELISA coated-strips. Samples were incubated with 100 µL of capture 
solution (mouse monoclonal anti-YKL-40 fAb conjugated to biotin) for one hour at room 
temperature. All incubation steps were performed covered (out of direct light) to prevent 
photobleaching. Reaction wells were emptied and washed with 300 µL of wash buffer 
solution three times. To the reaction wells, 100 µL of enzyme conjugate solution 
(polyclonal rabbit polyclonal anti-YKL-40 antibody conjugated to alkaline phosphate) 
was added and allowed to incubate at room temperature for one hour. Reaction wells 
were emptied and washed three times as described previously. One hundred µL of 
substrate solution (diethanolamine and magnesium chloride solution) was then added to 
well, and allowed to incubate for another hour at room temperature. To the final reaction 
solution, 100 µL of Stop solution (0.5 M NaOH) was added. Optical density of ELISA 
was read at 405 nm within 15 minutes of addition of stop solution. All samples were run 
in duplicate and concentrations were averaged. Any sample with confidence interval (CI) 
of greater than 25% between wells was rerun until the CI was less than 25%.  
Bio-Plex Assay 
Serum cytokine levels were determined using magnetic bead Luminex platform 
(Bio-Plex Pro Human Th1/Th2 Cytokine Panel, Biorad, Hercules, CA) per the 
manufacturer’s protocol. Briefly, the provided lyophilized standard was reconstituted in 
500 µL standard diluent for 30 minutes on ice and diluted as recommended. Samples 
were then diluted 1:4 in sample diluent. Magnetic beads were diluted to 1X concentration 
in assay buffer from 10X stock and 50 µL aliquots were distributed to each well of the 
fluorescent plate. Beads were washed two times with 100 µL of wash buffer. Once 
samples and standards were brought to room temperature, 50 µL of samples and 
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standards were distributed to each well. All samples and standards were run in duplicate. 
Reaction was incubated covered for one hour at room temperature with shaking at 600 
rpm. The plate was washed three times with 100 µL of wash buffer then 25 µL of 1X 
detection antibody solution was added to each well. Reaction was incubated covered for 
thirty minutes at room temperature with shaking at 600 rpm. The sample was again 
washed three times with 100 µL of wash buffer then 50 µL of 1X streptavidin was added 
to each well. The reaction was incubated covered for ten minutes at room temperature 
with shaking at 600 rpm. The plate was washed three times as described previously and 
magnetic beads were resuspended in 150 µL of assay buffer. The plate was read on a Bio-
plex (Bio-plex 200 System, Biorad) and data was acquired (Bio-plex Manager Software 
5.0, Biorad). Outliers on standard curve were removed after visual inspection. 
Concentrations for cytokines were calculated based on the average readings between 
duplicate cells.  
Statistical Analysis  
Clinical data from the YCAAD cohort was uploaded onto the YCAAD computer 
online database. Statistical analysis was performed using SPSS software version 20 
(IBM, Armonk, NY). Baseline values were only compared in children who also had 
available follow-up data. Nominal data was compared using the Fisher’s exact and 
Pearson’s Chi-Squared tests. All scaled data was confirmed to be of non-normal 
distribution using Shapiro-Wilk’s test, therefore, non-parametric tests, including 
Wilcoxon Signed-Rank, Mann-Whitney, and Sign test were used.  
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Definition of improvement in Asthma Control 
Improvement in asthma following surgery was defined by four distinct variables: 
ACT/TRACK reached MCID, any improvement in urgent care visits, any improvement 
in steroid courses, and composite improvement. The minimal clinically indicated 
difference (MCID) is a previously defined term that indicates the minimal difference in 
ACT or TRACK score that is associated with significant clinical outcomes. [63, 64] We 
used the previously described MCID scores as an improvement in ACT score greater than 
or equal to three or an improvement in TRACK score greater than or equal to 10. 
Although the MCID has not been formally described for the c-ACT questionnaire, we 
used the same cut-off that has been described for the teen/adult ACT score. We also used 
a composite score for improvement (composite improvement) in asthma control as 
defined previously [60] as any improvement in albuterol use frequency, decreased rate of 
steroid courses, decreased rate of urgent care visits, or a change in ACT /TRACK score 
that reached MCID.  
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RESULTS 
Baseline demographics YCAAD Cohort 
In an ongoing trial, over a 25-month period 136 children with asthma undergoing 
TA were enrolled with an average follow-up time of 7.2 months. Formal analysis was 
conducted when the first 100 children with asthma completed follow-up, with a follow-
up rate of 74%. One child was excluded from analysis because there was no clinician 
diagnosis asthma despite symptoms and medication use consistent with disease. The 
cohort was generally young (mean age 6.5), predominately male (63%), and with a large 
percentage of Hispanic children (44%). Consistent with current trends in TA for all 
children [47], 74% of children had their tonsils removed for SDB and 22% for recurrent 
tonsillitis. About one-third of children had either GERD or sinusitis and almost three-
quarters of children with asthma were atopic (Table 1).  
In parallel, 78 children without a diagnosis of asthma were also enrolled as 
controls. Fifty-seven of those children completed follow-up for a follow-up rate of 73%. 
Three children were excluded from analysis as they were diagnosed with asthma during 
the course of the study.  Compared with asthmatic peers, control subjects had less asthma 
related co-morbidities (i.e. sinusitis P = 0.018, GERD P = 0.004, and atopy P = 0.003, 
Mann-Whitney U), were less likely to be Hispanic, and were more likely to come from a 
higher socioeconomic background (Table 1).  
Improvement in Asthma Control Following TA 
Evidence of improvement in asthma symptoms after TA was demonstrated by 
comparing paired changes from baseline to follow-up in parent reported clinical 
outcomes. Urgent care visits (mean decrease from 2.37 to 0.78 visits per year, P < 0.001) 
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oral steroid courses (mean decrease from 1.74 to 0.5 visits per year, P < 0.001), and 
ACT/TRACK scores (median increase of adjusted ACT scores from 20 to 22, P < 0.001), 
all decreased in children following surgery (Figure 1). Children also had decreased use of 
controller medications (decrease from 52% to 37%, P = 0.004) but no significant change 
in albuterol use (P = 0.27).  
Circulating Inflammatory Markers after TA 
At baseline, children with asthma had higher levels of serum IL-5 (median 2.4 
pg/mL versus 1.0 pg/mL, P = 0.002) and IL-13 (median 1.7 pg/mL versus 0.9 pg/mL, P 
= 0.008) compared to non-asthmatic peers (Figure 2). In contrast, children without 
asthma had higher baseline levels of chitinase activity compared at baseline compared to 
children without asthma (median 3.8 nMol /mL*hr versus 3.2 nMol/mL*hr vs P = 0.014) 
(Summarized in Table 2).  
We found that neither chitinase activity (P = 0.63) nor YKL-40 levels (P = 0.26) 
changed following surgery (Table 2). The inflammatory cytokines IL-4 and IL-5 
significantly decreased (P = 0.022 and P = 0.002 respectively) selectively in children 
with asthma following TA (Figure 3).  IL-13 levels decreased in both children with and 
without asthma following surgery but were only significant for children without asthma 
(P = 0.088 and P = 0.029 respectively). All other cytokines did not significantly change 
following TA (Table 2). 
Effect of weight on improvement in asthma control following TA 
Because of the hypothesized impact of obesity on asthma control and the limited BMI 
data available in the YCAAD cohort, we compared the impact that a child’s weight had 
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on asthma control in two cohorts: the YCAAD Cohort (interim analysis of 88 children) 
and CT-Kids Cohort.   
Baseline demographics CT Kids Cohort 
Over a one-year period, 88 children with asthma undergoing TA were enrolled. 
One-year follow-up was completed for 76 (86%) children. BMI data was available for 49 
(66%) of the children who completed follow-up. LHW children made up of 61% of the 
cohort (n = 30) and overweight children 39% (n =19).  There was no significant 
difference between LHW and overweight children in age, gender, race/ethnicity, 
indication for tonsillectomy, or asthma related co-morbidities (summarized in Table 3A). 
Baseline demographics interim YCAAD Cohort 
An interim analysis on the effect of weight on asthma control was carried on the 
first 62 (86%) children with asthma that completed follow-up in the YCAAD Cohort. 
Strict BMI data was available for 47 (76%). Sixty-two percent of the cohort was LHW (n 
= 29) while 38% was overweight (n = 18). There was no significant difference between 
LHW and overweight children in sex, race/ethnicity, or asthma-related co-morbidities 
(Table 3A). Children in the overweight group were more likely to be older (range 2-17) 
compared with LHW peers (range 2-12, P = 0.01) and have tonsillectomy for sleep 
disordered breathing (P = 0.05).  
Baseline Asthma Control by Weight Category 
Baseline asthma control, as assessed by medication use, emergency room or 
urgent care visits, and missed school/work days was comparable between LHW children 
and overweight children in both cohorts (Table 3B). Additionally, in the YCAAD cohort, 
ACT scores were similar between LHW children and overweight children (P = 0.30). 
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Baseline oral steroid use was significantly lower for overweight compared to LHW 
children in the YCAAD cohort (P = 0.013) but was equivalent in the CT Kids cohort (P = 
0.57). 
Post-operative Asthma Medication Use by Weight Category 
At the follow-up visit—either at six months (YCAAD) or at one-year (CT-
Kids)—LHW children had decreased inhaled corticosteroid (ICS) use post-operatively 
(YCAAD, P = 0.008, CT Kids P = 0.016), while overweight children had no significant 
change in use (Table 3C, Table 3D). In the YCAAD cohort, frequency of albuterol use 
decreased in LHW children (median initial use of one time a week versus follow-up of no 
weekly albuterol use, P = 0.002), but did not change for overweight children. Leukotriene 
receptor antagonists (LTRA) were used less frequently post-operatively only for LHW 
children in the CT Kids cohort (P = 0.016). There was no significant change in long-
acting β2-agonists (LABA) in either cohort for both LHW and overweight children. The 
number of oral steroid courses decreased post-operatively for both cohorts of LHW 
children (P < 0.05, P < 0.02) but did not decrease significantly in overweight children in 
either cohort. 
Asthma Control and Health Care Utilization by Weight Category 
In the YCAAD cohort, ACT scores were significantly improved in LHW children (P = 
0.001) but not for overweight children (P = 0.48) following surgery (Table 3D). In the 
CT Kids Cohort, both LWH and overweight children had post-operative improvement in 
the number of emergency visits (P < 0.01, P < 0.05, respectively) and pediatrician visits 
(P = 0.001, P < 0.001) (Table 3C). Urgent care visits so decreased in both LWH and 
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overweight children in the YCAAD cohort but this change was not significant (Table 
3D). 
Clinical and Biomarker Characteristics that Impact Improvement in Asthma Control 
following TA 
For the first one hundred children in the YCAAD cohort with asthma who 
achieved follow-up, we identified baseline clinical and molecular signatures that 
correlated with improvement in asthma after TA.  
Minimally Clinical Indicated Difference in ACT and TRACK Scores  
Paired ACT, c-ACT, or TRACK scores were available for 74% of children. 
Improvement in asthma as defined by a MCID cutoff of a change of greater than three for 
the rescaled ACT score (see methods) and greater than 10 for the TRACK score. 
Improved asthma control occurred for 46% (n = 34) of children after TA. Children whose 
asthma improved were younger (median age 5.5 versus 7, P = 0.027), female (53% 
versus 27%, P = 0.03), on controller medications at baseline (68% versus 32% P < 
0.001), and children who had never been symptom free for one year (6% versus 23%, P 
= 0.055) were more likely to have improvement in ACT/TRACK score (Table 4). 
Indication for tonsillectomy, demographics, asthma triggers, and previous hospitalization 
history for asthma did not impact improvement in ACT/TRACK score following surgery 
(Table 4). 
For the children with ACT/TRACK score data, 80% (n = 60) had baseline 
cytokine data available and 95% (n = 70) had baseline chitinase activity/YKL-40 levels. 
Children whose asthma improved by MCID level following surgery had higher baseline 
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levels of IL-2 (P = 0.015), IFN-γ (P = 0.039), GM-CSF (P = 0.02) and TNF-α (P = 
0.04) (Table 4).  
Improvement in Urgent Care Visits 
Urgent care visits decreased for 41% (n = 41) of children with asthma following 
TA. Children who had improvement in ER visits were more likely to have exercise (P = 
0.023) and “other”  (P = 0.003) listed as asthma triggers, to be on controller medications 
(P < 0.001), to have moderate or severe asthma (P = 0.002), children who had never 
been symptom free for one year (P = 0.007), and to have had a higher number of lifetime 
hospitalizations (P = 0.04). There was also a higher frequency of children with sinusitis 
(P = 0.02) in the population who had a decrease in ER visits following TA (See Table 5).  
Cytokine data was available for 83% (n = 83) of children and chitinase and YKL-
40 levels were available for 94% (n = 94). Children who had improvement in ER visits 
had elevated IL-4 (P = 0.014), IL-4 (P = 0.023), and IL-13 (P = 0.013) (Table 5).  
Improvement in Oral Steroid Courses 
Steroid courses decreased for 39% (n = 39) of asthmatic children after TA. 
Children who had improvement in steroid courses were more likely to have “other”  (P = 
0.002) as an asthma trigger, have asthma that limited normal activities of daily life (P = 
0.043), to be on controller medications (P < 0.001), to have moderate or severe asthma 
(P < 0.001), to have had a higher number of lifetime hospitalizations (P = 0.018), to have 
been hospitalized in the year prior to surgery (P = 0.002). There was also a higher 
frequency of children with sinusitis (P = 0.007) in the population who had a decrease in 
steroid visits following TA (See Table 6).  
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Cytokine data was available for 83% (n = 82) of children and chitinase and YKL-
40 levels were available for 95% (n = 94). No baseline biomarker levels correlated with 
improvement in steroid courses following surgery (Table 6).  
Composite variable improvement 
Asthma improved for 70% (n = 70) of children with asthma following TA using 
the composite variable that has been previously described. [60] Children whose asthma 
improved more likely to be younger (P = 0.012), have “other”  (P = 0.002) as an asthma 
trigger, to be on controller medications (P < 0.001), to have moderate or severe asthma 
(P = 0.001), and to never have been symptom free for one year (P = 0.001) (Table 6).  
Cytokine data was available for 83% (n = 83) of children and chitinase and YKL-
40 levels were available for 94% (n = 94). No baseline biomarker levels correlated with 
improvement in steroid courses following surgery (Table 6). Children whose asthma 
improved had elevated IL-4 (P = 0.042), IL-4 (P = 0.025), and IL-13 (P = 0.029) and 
TNF-α (P = 0.041) levels at baseline compared to peers whose asthma did not improve 
(Table 6). 
Decreases in IL-5 Correspond to Improvement in Asthma Control  
To observe if changes in inflammatory cytokines impacted improvement in 
asthma control after surgery, we compared median changes in cytokines levels in 
children whose asthma improved versus did not improve. Interleukin-5 levels dropped in 
children who had improvement in urgent care visits (-1.3 pg/mL versus -0.2 pg/mL, P = 
0.021), number of steroid courses (-1.25 pg/mL versus -0.15 pg/mL, P = 0.022), and 
overall composite control of asthma (-1.2 pg/mL versus -0.05 pg/mL, P = 0.008) after 
surgery compared to peers who did not improve. Neither changes of IL-4 (composite 
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improvement, P = 0.09;  urgent care improved P = 0.13; steroids improved, P = 0.95) 
nor IL-13 (composite improvement, P = 0.51;  urgent care improved P = 0.11; steroids 
improved, P = 0.70)  correlated with improvement in asthma.  
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DISCUSSION 
Though retrospective cohort studies have examined the role of TA on asthma 
control and healthcare utilization, this is the first study that identifies inflammatory 
markers and specific patient characteristics that may predict improvement in asthma after 
TA. In addition, this is the first study that demonstrates that TA modulates Th2 
inflammation in asthmatic children, which may play an important role in explaining 
symptoms resolution after surgery.  
Baseline Cohort Demographics 
In general, our cohort is similar to other pediatric asthma cohorts. The male 
predominance, large Hispanic population, and higher rates of asthma co-morbidities 
compared with the general population, are consistent with other pediatric asthma cohorts. 
One notable difference is that the mean age is significantly younger in our cohort. The 
younger age may be explained by the general trend in pediatric asthma research to delay 
enrollment of children until age six. Because wheezing is a common occurrence in the 
pre-school aged child [13], frequently birth cohorts delay official diagnosis of asthma 
until a child can undergo pulmonary function testing with bronchodilator response at age 
six. [9, 14, 37] Therefore, because our study does not rely on PFTs for diagnosis we may 
capture a few children with recurrent wheezing of childhood rather than asthma. On the 
other hand, this study may capture an earlier life intervention that could impact natural 
history of disease.  
Another notable difference between our asthmatic population and control subjects 
was the difference in maternal education level. Control subjects were more likely to have 
parents with an advanced educational background compared to asthmatic subjects. 
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Although there is not an evident explanation for this distinction, it is possible this effect 
may be partially explained by a reluctance of parents with a less education to enroll their 
children in clinical research if the results do not directly apply to their child.  
Asthma Improves Following TA 
There was robust clinical improvement in asthma control—including 
improvement in ACT/TRACK scores, urgent care visits, and steroid courses—following 
TA. This clinical improvement is likely a multifactorial resulting from improvement in 
overall airway resistance, decreasing potential for microaspiration, and decreasing 
systemic inflammation.    
There has been increasing interest in the role for microaspiration in the worsening 
of asthma control. Bacterial toxins and bacterial colonizers of the nasal passage, 
adenoids, and tonsils may be silently aspirated in the lungs, thereby triggering worsening 
inflammation of the lower airways. [65] In children with adenoid hypertrophy there may 
be increased stasis of nasal secretions and increased bacterial colonization of tissue 
leading to increased susceptibility for antigen triggering of the lower airways, thereby 
worsening asthma control. Therefore, by removing the nidus of inflammation, there may 
decreased triggering of the lower airways and improved asthma control.  
Alternatively TA may improve asthma symptoms by decreasing systemic inflammation. 
In children with adenotonsillar disease there may be low-level systemic inflammation as 
a consequence of misregulation of normal adenoid and tonsillar immune function[49] or 
from systemic inflammation associated with long-standing OSA/SDB. Sleep disordered 
breathing in children is associated with higher levels of pro-inflammatory cytokines 
associated with asthma including hs-CRP, leptin, and adiponectin.[46] Therefore, if 
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surgery decreases low-level circulating pro-inflammatory agents, it may contribute to 
improving airway inflammation leading to overall improvement in asthma control (See 
below). 
Biomarkers of Th2 associated asthmatic inflammation improve following TA 
Although improvement in asthma control following TA has been described 
previously, less is known about its impact on asthmatic inflammation. Inflammatory 
cytokines are an appealing target as a post-tonsillectomy biomarker as Th2 inflammatory 
cytokines are expressed by CD4+extrafollicular T-cells in pediatric tonsillar tissue. [66] 
Additionally, it was previously found in our lab that Serpin B2—a gene that is regulated 
by IL-4 and IL-13 in vitro [60, 67]—expression levels decrease in children whose asthma 
improves following surgery [1], thereby suggesting a connection between Th2 cytokine 
pathways and TA.  
There was a significant decrease in IL-4 and IL-5 levels in the serum of asthmatic 
children following TA. Interleukin-4 and IL-5 are two of the classically described 
cytokines involved with Th2 allergic inflammation in asthmatic children. Therefore, if 
TA modulates expression of inflammatory cytokines involved with asthma pathogenesis, 
it may explain the improvement in asthma symptoms following surgery.  
Interleukin-4 has a broad range of clinical activities but in asthma it may initiate 
allergic sensitization and prime the Th2 immune response leading to recruitment of 
eosinophils into the airway, increasing bronchial hyperreactivity, and elevating IgE 
levels. [68, 69] Expression of IL-4 is increased at both the proteomic and genomic level 
in the bronchoalveolar lavage fluid (BALF) of asthmatics. A decrease in IL-4 levels 
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following surgery may modulate Th2 response and decrease allergic sensitization, 
thereby improving asthma symptoms.   
Despite the decrease in IL-4 levels in children following TA, this decrease did not 
correlate with clinical improvement of asthma. The absence of improvement is consistent 
with efforts to target IL-4 therapeutically in adult asthmatics; Phase II trials that targeted 
IL-4 expression using either soluble IL-4R or anti-IL-4 antibodies did not improve 
asthma symptoms or improve FEV1. [70, 71] The failure of anti-IL-4 agents suggests that 
IL-4 may be more important in the initial allergic sensitization phase compared to long-
standing remodeling and disease persistence. [72, 73] Additionally, IL-4 levels were 
difficult to detect in the serum, therefore differences in expression were subtle and the 
entire impact of the effect of surgery on this biomarker may not be fully captured by our 
assay. Therefore, modulation of expression of IL-4 in the serum of asthmatic children, 
may have less clinical relevance in describing improvement in asthma following TA.  
Interleukin-5 is another important Th2 cytokine in allergic asthmatic 
inflammation that contributed to response to TA in our cohort. Interleukin-5 promotes the 
maturation, activation, and mobilization of eosinophils within the lung in atopic 
asthmatic individuals. Exogenous exposure to IL-5 increases sputum eosinophilia and 
airway hyperresponsiveness. [74] Interleukin-5 is overexpressed in the serum and in the 
BALF in asthmatic individuals and mRNA expression has been shown to correlate with 
asthma severity. [75, 76] Similarly, we found that children with asthma had higher levels 
of circulating IL-5 compared with non-asthmatic peers. As atopic asthmatic 
inflammation—the most commonly described type of asthmatic inflammation in 
children—is characterized by eosinophillic infiltration and bronchial 
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hyperresponsiveness, a decrease in IL-5 levels could decrease asthmatic inflammation 
following surgery.  
Interleukin-5 levels decreased in our cohort following TA and a decrease in 
circulating levels correlated with improved urgent care visits and overall control. There 
may be elevation of serum IL-5 in children with acute asthma exacerbation and levels 
decreases once asthma is stabilized [77], suggesting a decrease in IL-5 levels may 
correlate with improved asthma control. Unlike attempts to target IL-4, therapeutic agents 
that target IL-5 have had modest success in improving asthma symptoms in patient 
cohorts with significant sputum eosinophilia with a history of frequent exacerbations. 
[75] The best-described anti-IL-5 agent is the humanized monoclonal antibody 
Mepolizumab (SB240563, GlaxoSmithKline, Research Triangle Park, NC), which in 
phase II trials in patients with significant sputum eosinophilia on chronic ICS has shown 
to decrease asthma exacerbations. [78] In adults with significant response to 
Mepolizumab decreasing peripheral eosinophil counts, rather than measuring serum IL-5, 
are the standard of response to therapy. Although serum eosinophil counts were 
unavailable for our cohort, future correlation in circulating eosinophils would enrich our 
understanding of response to surgery., In children who have a change in IL-5 expression 
following surgery there may be improvement in symptoms secondary to decreasing 
airway eosinophilia.  
Interleukin-13 levels were also elevated in the serum of asthmatic children 
compared to controls. Interleukin-13 is another Th2 cytokine also present in the asthmatic 
airway. Although similar in structure and function to IL-4, it is thought perpetuate of 
allergic airway response rather than to initiate response.[79] Unlike IL-4 and IL-5 levels, 
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IL-13 did not significantly decrease in asthmatic children following surgery. It is possible 
that IL-13 levels did not fall following surgery as in general they were expressed at lower 
levels in the serum compared to IL-4 and IL-5 and levels may be suppressed by oral 
steroid use, therefore biological proteomic assays may not be able to detect levels are 
readily as other cytokines. In contrast, IL-13 did decrease significantly in children 
without a clinician diagnosis of asthma. This change suggests that even in children 
without asthma, TA may impact systemic inflammation.   
Previously in the YCAAD cohort we found that asthmatic children undergoing 
TA, in addition to having post-operative improvement in asthma control, had a decrease 
in chitinase activity.[60] With enlargement of the cohort, this effect was eliminated; there 
was no significant decrease in chitinase activity in children with or without asthma 
following surgery. Additionally, control subjects had higher baseline chitinase activity 
compared with asthmatic peers. This contradicts previous findings that serum 
chitotriosidase is elevated in the serum of asthmatic individuals compared with controls. 
[32] As chitotriosidase has been found to be overexpressed in the hypertrophied adenoids 
of children with chronic rhinosinusitis, otitis media with effusion, and allergic rhinitis 
[80], in children with adenotonsillar disease chitinase activity may reflect degree of 
adenotonsillar inflammation rather than asthmatic inflammation, therefore decreasing its 
utility as an asthma biomarker in the setting of adenotonsillar disease. Alternatively, this 
study did not address the role of genetic mutations of chitotriosidase and difference in 
expression may be a result of differing genetic background between asthmatic and non-
asthmatic children in our cohort.   
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Clinical Characteristics that May Predict Improvement in Asthma Following Surgery  
Though previous studies have examined the role of TA on asthma control and 
healthcare utilization, this is the first study that identifies specific clinical 
characteristics—such as being LHW, being younger, being female, having a history of 
sinusitis, and having persistent asthma—correlated with improvement in asthma 
following surgery. 
Children who are overweight receive less benefit from TA for asthma control compared 
to LHW peers  
We found in two independent cohorts that LHW children are more likely to have 
clinical improvement in asthma control and medication usage following TA compared to 
their overweight peers. LHW children used less asthma medications post-TA and had a 
more robust increase in ACT scores while overweight peers had no significant change in 
medication use or ACT scores. The strong decline in oral steroid courses post-operatively 
for LHW children in both cohorts suggests a decline in frequency of asthma 
exacerbations following surgery that was more robust in LHW children compared to 
overweight peers.  
The absence of change in ICS use for overweight children may reflect a general 
increased resistance to inhaled corticosteroids in obese asthmatic children. Forno et al 
found that overweight asthmatic children were less likely to have improvement in lung 
function following budesonide administration compared with non-overweight weight 
peers. [81] Obesity-associated inflammation may contribute to persistence of clinical 
resistance to ICS post-operatively, especially as pro-inflammatory cytokines have been 
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implicated in the regulation of the expression of the β-isoform of the glucocorticoid 
receptor associated with resistance to ICS in asthmatic adults. [82, 83] 
Overweight children may receive less benefit in asthma control following TA 
because of persistent mechanical obstruction of the upper airway secondary to redundant 
neck soft-tissue and adiposity. Even at baseline in the YCAAD cohort, overweight 
children were more likely to have TA for obstructive airway disease compared to 
recurrent tonsillitis. Chu et al observed that in children undergoing TA for OSA, 59% of 
obese children have persistent polysomnographic evidence of OSA post-operatively 
compared with less than 22% of non-obese children. [84] Persistence of upper airway 
obstruction after TA may contribute to lack of improvement in asthma control.  
Alternatively, obesity-associated asthma may be associated with Th1 
inflammation compared with the Th2 atopic phenotype found in classical pediatric 
asthma. [20, 85] If removal of the adenoids and tonsils predominately impacts Th2 
inflammatory pathways, the impact on asthmatic inflammation may be less dramatic for 
obese asthmatic children. Persistence of upper airway obstruction in obese children post-
operatively may contribute to continued activation of inflammatory pathways that 
influence asthma control, especially as both obstructive sleep apnea and sleep disordered 
breathing are associated with increased expression of pro-inflammatory markers such as 
IL-6 and hs-CRP. [46, 86, 87] 
Interestingly, with enlargement of the cohort to 100 children in the YCAAD 
cohort, neither BMI percentile nor parent adjusted weight correlated with improvement in 
asthma. The effect of being overweight may have been diminished in larger sample size 
as the robust improvement following TA may modulate the effect of obesity on 
	   Koenigs et al. 44 
improvement. A more detailed understanding of the obesity sub-phenotypes, including 
measurements such as waist-circumference and percent body fat, may further elucidate 
the importance of obesity on post TA improvement in asthma control.  
Asthma control in younger children is more likely to improve following TA 
Younger children were more likely to have improvement in their asthma control 
after TA as measured by the ACT, c-ACT, or TRACK scores and by the composite 
variable for improvement. Younger children with asthma are at higher risk for 
hospitalization and have significantly longer hospitalizations compared with older peers. 
[88] As younger children have anatomically narrower lower airways compared to older 
peers, they are at increased risk for obstruction with inflammation, often in the setting 
viral infections. Therefore, TA has the potential to reduce disease burden in this at risk 
population. 
Age is also an important factor both anatomically and physiologically in 
adenotonsillar disease. The adenoids to airway ratio size is largest in children ages two to 
eight [52], therefore, in younger children there is an increased likelihood that adenoid 
hypertrophy may cause obstruction of airflow. As nasal airflow plays an important role in 
humidification, warming, and filtering inspired antigens, the increased airway obstruction 
in younger children may play a significant role in exacerbating asthma control. [2, 89] 
Additionally, adenotonsillar disease is considered to be the primary risk factor for OSA 
and SDB in younger children. Magnetic resonance imaging shows a direction correlation 
between increasing adenoid and tonsillar volume in relationship to airway size with an 
increasing apnea-hypopnea index. [53] Bhattacharjee et al found in a cohort of 578 
children that following adenotonsillectomy, children had improvement in apnea-
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hypopnea index and total sleep time, suggesting improvement in OSA following 
surgery.[58] Interestingly, this effect was diminished in subjects older than age seven, 
suggesting TA may have greater benefit in improving OSA symptoms for younger 
children. Sleep disordered breathing and OSA may worsen asthma control through by 
increasing systemic circulatory inflammation [46] increasing neurocirculatory 
bronchoconstriction, or worsening of GERD. [2] Therefore, if there is greater 
improvement OSA and SDB following TA in younger children, they may receive 
superior improvement in asthma control.  
Beyond anatomical considerations, the tonsils and the adenoids are most 
immunologically active in younger children. Although the exact immune function of the 
tonsils remains to be elucidated, they are thought to play a significant role in antigen 
surveillance, immunoglobulin production, and the development of adaptive immune 
response. [49, 90]  In children with OSA, there is increased proliferation of T-cells and 
expression of the pro-inflammatory cytokines TNF-alpha, IL-1 alpha, and IL-6 within 
tonsillar tissue, suggesting that adenotonsillar hypertrophy may contribute to increasing 
overall systemic inflammation. [90, 91] Especially as lymphocytes activated in the 
tonsillar tissue can selectively migrate to the lung [92], increased tonsillar inflammation 
may lead to lower airway inflammation in children with asthma. Therefore, in younger 
children who have more immunologically robust tonsillar tissue, there may be and 
increased role in adenotonsillar disease and contribution to lower airways inflammation.  
One of the major challenges with assessing asthma in younger children is that 
clinician diagnosis of disease frequently occurs without objective pulmonary function 
tests. Considering that wheezing is common in early childhood, it is possible that we are 
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capturing improvement in children transient wheezing of childhood rather than with a 
true diagnosis of asthma. Nevertheless, the improvement in clinical outcomes suggests 
that TA may be particularly beneficial in a young pediatric cohort.  
Asthma control is more likely to be improved in girls than boys following 
adenotonsillectomy 
After TA we found that females were more likely to have a clinically significant 
improvement ACT or TRACK scores compared to male peers. There is well-described 
gender imbalance in pediatric asthma, where boys are twice as likely to wheeze under the 
age of ten compared to girls. [93, 94] This trend reverses during puberty with an 
increasing incidence in asthma in females during adolescence.  It has been hypothesized 
that male children are at increased risk for asthma in early childhood because of smaller 
airway diameter [95] and increased allergen sensitization compared to female peers. 
Males have increased level of IgE compared to females. [96, 97] and are more likely to 
have positive allergy skin testing compared to female peers. [96, 98] This gender 
inequality also translates into clinical disease severity as younger boys were more likely 
to have increased length of hospitalization in childhood compared to female peers. [88] 
Therefore, if male children have underlying anatomic and inflammatory susceptibility 
that puts them at increased risk for worse control, they may not receive the same benefit 
from surgery.  The fact that gender only significantly impacted the asthma control scores 
and not changes in urgent care visits, steroid courses, or composite improvement, it likely 
plays a lesser role in predicting improvement after TA.   
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Children with baseline sinusitis have decreased urgent care visits and steroid courses 
following TA 
A history of baseline sinusitis correlated with improvement in urgent care visits 
and steroid courses following TA. Sinus disease has a higher prevalence in both children 
and adults with asthma than in the general population. [2, 99] Chronic rhinosinusitis may 
trigger asthmatic inflammation through post-nasal drainage of inflammatory mediators, 
shared mucosal inflammatory mediators between the nasal passages and the lower 
airways, and pharyngobronchial reflux. [65] Previously, it has been shown that both 
medical treatment (nasal steroids, antimicrobial agents, and oral decongestants)[100] and 
surgical management (functional endoscopic sinus surgery) [101, 102] decreased 
requirements for glucocorticoids, decreased asthma-related hospitalizations, missed 
school days, and improved lung function. [65]  
The high of baseline history of sinus disease in our cohort suggests that sinusitis 
worsens baseline asthma control in the setting of adenotonsillar disease. Adenoid 
hypertrophy aggravates sinus disease by acting as a local reservoir for the local spread of 
bacterial flora to the sinuses and by mechanical outflow obstruction of nasal secretions. 
[103, 104] Adenoidectomy is an alternative treatment for refractory sinusitis in children. 
[105] Vandeburg et al found that 50-79% of children with rhinosinusitis refractory to 
medical management had improvement in symptoms following adenoidectomy.[106] 
Consistent with our findings, for asthmatic children with chronic rhinosinusitis TA may 
be particularly beneficial in improving asthma symptoms following surgery.  
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Children with Persistent Asthma have improvement in asthma control following TA  
The impact of persistent asthma on lung function is profound. In the Tucson 
cohort children who have persistent wheezing by age six are more likely to have long-
term decrease in lung function. [13] Persistent asthma is especially challenging to 
manage clinically in children. The mainstay of treatment for persistent asthma is inhaled 
corticosteroids, but in younger children adequate medication delivery through inhalers is 
less reliable and there are concerns for long-term metabolic consequences. Although 
there is recent evidence that oral LTRA may be an alternative therapy to improve asthma 
symptoms in young children [107], there is still a need for improvement in management 
of persistent disease.  
The decrease in controller medication use following surgery suggests that TA 
may play a role in altering inflammatory pathways that lead to persistence of disease. Not 
only did controller use decrease as a result of TA, but also children on controller 
medications were also more likely to have improvement in asthma following surgery in 
all improvement variables.  Additionally, children who had a one-year symptom free 
period were less likely to have improvement in asthma control and health care utilization 
for asthma. At baseline, children with persistent disease might have a higher likelihood to 
improve because they had worse baseline metrics (higher number of emergency room 
visits, lower baseline ACT/TRACK scores, and higher hospitalization rate) compared to 
children not on controllers. But beyond baseline metrics, children on controller 
medications were more likely to have chronic allergies and rhinosinusitis, suggesting a 
more atopic phenotype with higher baseline levels of IL-4 and IL-5. Therefore, a baseline 
inflammatory Th2 profile may contribute to why children improve following surgery. 
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Not only did persistence of asthma symptoms influence improvement, but 
severity of asthma impacted which children received benefit from surgery; moderate to 
severe asthmatics had a greater improvement in asthma control compared to mild 
asthmatics. This difference may be explained partially by inequality of baseline metrics, 
but also may reflect the relationship between upper airway obstruction and worsening 
asthma control in severe asthma. Severe and moderate asthmatics are more likely to have 
OSA compared to mild-asthmatics. [46] Therefore, in children—where adenotonsillar 
disease is the major contributor to OSA—removal of the tonsils and adenoids may have a 
more profound impact on children with moderate to severe disease rather than to children 
with milder disease.  
Inflammatory asthma biomarkers are elevated in children’s whose asthma improves 
following TA 
Children whose asthma improves following TA have elevation of Th2 Cytokines prior to 
surgery 
Serum levels of IL-4, IL-5, and IL-13 were elevated in children who had improvement in 
overall asthma control and in urgent care visits following TA. Although the specific 
actions of these cytokines in asthmatic inflammation have been discussed previously (See 
Biomarkers of Asthmatic Inflammation Improve Following TA), it is worth noting the 
importance of these markers in the classical Th2 inflammatory response associated with 
allergic asthma. Because an increase in Th2 immune response is thought to be a driving 
force for inflammatory infiltration and development of bronchial hyperreactivity in 
asthma in early-onset atopic asthma, elevation of these cytokines at baseline suggests that 
the individuals who receive the most benefit from surgery are children who have an 
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asthma phenotype associated with early-onset Th2 inflammation.[108] Additionally, 
expression of IL-5, and IL-13 also correspond with asthma severity and poorer control. 
[109, 110] As more severe asthmatics are more likely to have improvement following 
surgery, elevation of cytokine levels may reflect baseline severity in addition to atopic 
phenotype associated with improvement.  
Non-Th2 inflammatory cytokines are elevated in asthmatics whose asthma improve after 
surgery 
In our cohort we found that TNF- α, GM-CSF, IL-2, and IFN-gamma were 
elevated in children who had clinically significant improvement in ACT/TRACK scores 
after surgery. Tumor necrosis factor-α is an inflammatory cytokine that is essential for 
leukocyte recruitment, expression of vascular endothelial growth factors, and stimulation 
of fibroblasts and smooth muscles cells. Inhalation of exogenous TNF-α leads to airway 
hyper-responsiveness and increased sputum neutrophils counts, similar to asthmatic 
inflammation. [16] Tumor necrosis factor-α may be essential in that pathophysiology of 
acute exacerbations as acute exacerbations are related increased sputum neutrophilia. 
[111] The baseline elevation of TNF-α in our cohort may be related to poorer baseline 
control and recent asthma exacerbation as children with lower baseline scores (thus 
suggesting increased likelihood of recent exacerbation) as lower baseline scores correlate 
significantly with change in ACT/TRACK score after TA. As the ACT evaluates asthma 
control over relatively short time period of four weeks, if a child has had worsening 
asthma control and associated changes in circulating TNF-α during that period it would 
be captured in a lower baseline score.  
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Children whose ACT score reached MCID following adenotonsillectomy also 
were more likely to have increased baseline expression of GM-CSF compared to those 
who did not improve. Overexpression of GM-CSF in the lungs in animal shows severe 
lung eosinophilia, alveolar macrophage expansion and fibrosis consistent with asthmatic 
inflammation. [112] In humans, genetic polymorphisms of GM-CSF are related to 
asthma. [113] Although physiologic expression GM-CSF may play an essential role in 
priming Th1 immunity, with its overexpression there is an imbalance of cytokine and 
chemokine response as overexpression leads to transient increased expression of IL-4 and 
IL-5. [114] Therefore, in children with elevated GM-CSF at baseline it is possible that 
they have misregulation of Th2 cytokine expression. As improvement in asthma 
following surgery correlates with IL-5 regulation, misregulation of GM-CSF may 
contribute to a baseline inflammatory profile that identifies children whose asthma 
improves following surgery.  
We found that baseline elevation of IL-2 and IFN-γ was associated with clinically 
significant improvement in ACT/TRACK scores following surgery. Interferon-γ and IL-2 
are cytokines most frequently associated with Th1 response, a response that is generally 
suppressed in asthmatics. [16, 115] Interferon-γ specifically manipulates the balance of 
Th1 and Th2 inflammation. But studies looking at BALF of asthma found that in severe 
asthmatics there is elevation of IFN-γ and IL-2. [16, 116] Additionally, there may be 
overproduction of IFN-γ by CD8+ T-cells in asthmatic individuals, but levels are not 
significant enough to exceed the exaggerated Th2 response. [115] Therefore, the 
elevation of IFN-γ and IL-2 in children whose asthma improves following surgery 
suggests a phenotype associated with generalized elevation systemic inflammation. As 
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increased total systemic inflammation is associated with asthma persistence and severity, 
baseline elevation of IFN-γ and IL-2 may help identify persistent asthmatics who may 
improve post-operatively. (See Children with Persistent Asthma have improvement in 
asthma control following TA).  
Study Strengths and Limitations  
A major strength of this study is that we correlated both clinical and biological 
data to improvement in asthma after surgery. To our knowledge this is the largest cohort 
of pediatric asthma patients undergoing adenotonsillectomy and the only cohort that has 
both clinical and biological data.  
Continued follow-up of this cohort would demonstrate if the effect of TA has a 
long-standing effect on the natural history asthma or a more transient effect in the 
relatively short follow-up time. Further comparison of the biological and clinical 
response to TA with asthmatic children undergoing surgery other than TA would aide in 
understanding the direct relationship of clinical and biologic response after TA. 
Comparison with an asthma surgical control group would also help to account for the 
placebo effect of surgery on improving asthma control.  
Additionally, the majority of therapeutic research in the pediatric population 
occurs in school-aged children in order to minimize the risk of treatment in the very 
young child. Therefore the largest pediatric asthma cohorts have an average age of about 
nine [37], thereby making interpretation of clinical outcomes for our younger cohort 
compared to other interventions more difficult. Furthermore, characterization of OSA 
pre-operatively would also help characterize the degree of upper airway obstruction in 
children prior to surgery. Nocturnal polysomnography (PSG) is increasingly used in 
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pediatric population for the diagnosis and management of OSA. As children with 
recurrent tonsillitis and OSA can have tonsillar hypertrophy and SDB, further 
characterization with nocturnal PSG may aide in helping to determine the role of tonsillar 
hypertrophy and functional obstruction on asthma control.  
CONCLUSIONS AND FUTURE DIRECTIONS 
This is the first study that specifically connects specific patient characteristics—
both clinical and biological—to improvement in asthma after TA. By characterizing a 
phenotype of child whose asthma responds to surgery, we eventually may be able to 
predict which children with asthma will have a response to TA. By predicting which 
children will have a good response to surgery, it is possible that asthmatic children 
without standard indications for TA could be identified that may receive benefit from TA 
selectively for asthma control. Additionally, to our knowledge, this is the first time 
anyone has demonstrated that TA modulates the allergic response found in asthmatic 
children and that modulation of this response corresponds to improvement in asthma. 
Further characterization of this allergic response is needed to better understand the 
complex pathways that drive the marked clinical improvement and to determine if this 
modulation has long-lasting impact on asthma control.  	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TABLES 
	  
Table 1. Baseline Demographics of YCAAD Cohort. P-values represent comparisons 
between asthma and control populations. *Fisher’s exact, ≠Pearson’s χ2,  °Mann-Whitney 
U Test.  
 
 	  	  	  	  	  	  
Variable Asthma  
n = 100 
Controls  
n=54 
P-value 
Age  
Mean [Range] 
6.5 [2-17] 5.7 [2-18] 0.09° 
Male Gender (%) 63 50 0.13* 
Race (%) 
White/Caucasian 
African American 
Asian 
Other 
 
77 
17 
0 
6 
 
72 
26 
2 
0 
0.086* 
Latino Ethnicity (%) 44 21 0.02≠ 
BMI Percentile  
Mean [Range] 
65 [0-100] 68 [0.2-99] 0.92° 
Gross Income (%) 
< 19,999 
20,000-39,999 
40,000-59,999 
60,000-99,999 
>100,000 
Declined 
 
26 
24 
14 
18 
16 
2 
 
19 
17 
7 
24 
33 
0 
0.09≠ 
Maternal Education (%) 
< 8th Grade 
Some HS 
HS Graduate 
Trade School 
College Graduate 
Graduate School 
Declined 
 
0 
10 
43 
17 
23 
6 
1 
 
4 
4 
30 
13 
24 
24 
1 
0.009≠ 
Location (%) 
Rural 
Suburban 
Urban 
Declined 
 
12 
51 
36 
1 
 
15 
59 
26 
0 
0.51≠ 
Second Hand Smoke  31 29 0.84* 
Indication TA 
SDB/OSA 
RT 
Other 
 
74 
22 
4 
 
80 
20 
0 
0.31≠ 
Asthma Comorbidities (%) 
Sinusitis 
Atopy 
GERD 
 
39 
78 
36 
 
20 
53 
13 
 
0.018* 
0.003* 
0.004* 
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Biomarker Asthma  Controls Baseline 
 Pre Post ∞P-value Pre Post ∞P-value °P-value 
Chitinase 
Activity 
3.2 
[0.2-35] 
3.6 
[0.2-22] 
0.63 3.8 
[1.0-15] 
4.0 
[0-11.5] 
0.26 0.014 
YKL-40 32 
[13-194] 
34 
[8-171] 
0.58 32 
[9-234] 
31 
[7-85] 
084 0.51 
IL-2  2.4 
[0-1062] 
3.3 
[0-628] 
0.23 2.5 
[0-100] 
0  
[0-74.14] 
0.39 0.39 
IL-4  0.5 
[0-6.6] 
0.3 
[0-2.7] 
0.022 0.5 
[0-13] 
0.3 
[0-8.15] 
0.21 0.82 
IL-5   2.4 
[0-31.6] 
1.2 
[0-7.2] 
0.002 1.0 
[0-35] 
0.9 
[0-14] 
0.15 0.002 
IL-10 7.5 
[0-1918] 
6.7 
[0-787] 
0.66 9.6 
[0-66] 
5.1 
[0-76] 
0.41 0.80 
IL-12 7.5 
[0-6787] 
2.6 
[0-2729] 
0.79 0 
[0-368] 
0 
[0-340] 
0.44 0.06 
IL-13  1.7 
[0-64] 
0.9 
[0-20] 
0.088 0.7 
[0-37] 
0.6 
[0-6.1] 
0.029 0.008 
IFN-γ  30 
[0-1014] 
24 
[0-494] 
0.062 41 
[0-680] 
29 
[0-905] 
0.329 0.57 
TNF-α  6.9 
[0-500] 
5.1 
[0-971] 
0.95 4.0 
[0-186] 
2.5 
[0-65] 
0.40 0.064 
GM-CSF  12 
[0-1136] 
11 
[0-158] 
0.45 19 
[0-162] 
9.9 
[0-192] 
0.11 0.67 
 
Table 2. Asthma Biomarkers in response to TA. P-values represent ∞Wilcoxon Rank Sum and 
°Mann-Whitney U. Baseline represents comparison of biomarker data between children with 
asthma and controls on the day of surgery. Values represent median and range is demarcated by 
[ ]. Cytokine levels are in pg/mL, YKL-40 in ng/mL and Chitinase Activity in nMol/mL*hr.  
  
 
 
 YCAAD (n=47)  CT Kids (n = 49)  
 LHW 
(n=29) 
Overweight 
(n=18) 
P-
value 
LHW 
 (n=30) 
Overweight  
(n= 19) 
P-value 
Age 5.8 [2-10] 8.7 [2-17] 0.023* 6 [2-16] 7.5 [2-15] 0.24* 
Gender 
Male 
Female 
 
18 (62) 
11 (38) 
 
9 (50) 
9 (50) 
0.55§  
19 (63) 
11 (37) 
 
11 (58) 
8 (42) 
0.77§ 
Race  
White 
African-American 
Other 
 
26 (90) 
2 (7) 
1 (3) 
 
12 (67) 
6 (33) 
0 
0.06≠  
27 (90) 
2 (7) 
1 (3) 
 
12 (90) 
1 (5) 
1 (5) 
0.93≠ 
Hispanic 12 (41) 11 (61) 0.24§ 3 (10) 2 (11) 1.00§ 
Indication 
OSA 
Tonsillitis 
Other 
 
16 (55) 
11 (38) 
2 (7) 
 
16 (89) 
5 (11) 
0  
0.05≠  
21 (72) 
1 (3.4) 
7(24) 
 
10 (59) 
4 (23.5) 
3 (18) 
0.11≠ 
Co-morbidities 
Atopy 
Sinusitis 
GERD 
 
18 (64) 
9 (31) 
14 (48) 
 
15 (88) 
8 (44) 
4 (22) 
 
0.20§ 
0.37§ 
0.12§ 
 
23 (77) 
4 (13) 
4 (13) 
 
12 (63) 
2 (10.5) 
4 (21) 
 
0.35§ 
1.00§ 
0.69§ 
 
Table 3A. Baseline demographics interim YCAAD Cohort and CT-Kids Cohort. Age 
expressed as mean, all other values represent n. () represent percentage, [ ] represent range,* 
Mann-Whitney, ≠Pearson’s χ2 test, and §Fisher’s Exact Test.  
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 YCAAD (n=47)  CT Kids(n = 49)  
 LHW 
(n =29) 
Overweight 
(n=18) 
P-value LHW   
(n=30) 
Overweight  
(n=19) 
P-value 
Medication Use 
ICS 
LTRA 
LABA 
 
19(65) 
7 (24) 
5 (17) 
 
10 (55) 
4 (22) 
1 (6) 
 
0.55§ 
1.00§ 
0.35§ 
 
26 (87) 
16 (53) 
2 (7) 
 
12 (63) 
8 (42) 
1 (5.3) 
 
0.08§ 
0.56§ 
1.00§ 
Albuterol Use 
≥3 times per day 
1-2 times per day 
2-3 times per 
week 
Once a week or 
less 
Never 
 
4 (14) 
3 (11) 
3 (11) 
5 (19) 
12 (44) 
 
1 (6) 
2 (12) 
1 (6) 
8 (47) 
5 (29) 
0.34≠ 30 (100) 19 (100) 1.00§ 
Oral Steroid 
Courses 
1.45 [0-8] 0.33 [0-4] 0.013* 0.97 [0-4] 0.95 [0-4] 0.57* 
Urgent Care Visits 2.86 [0-50] 0.72 [0-6] 0.15* 0.67 [0-5] 0.53 [0-3] 0.43* 
Pediatrician Visits N/A N/A  6.48 [0-30] 4.94  [0-17] 0.65* 
Baseline ACT™ 18 [7-27] 22 [17-27] 0.30* N/A N/A N/A 
 
Table 3B. Baseline Asthma Control and Healthcare Utilization of interim YCAAD Cohort 
and CT-Kids Cohort. Medication use and Albuterol expressed as n, all other values represent 
mean. () represents percentage, [ ] represent range,    *Mann-Whitney, ≠Pearson’s χ2 test, and 
§Fisher’s Exact Test. 
 
 
 
 
 
 
 
  LHW   Overweight  
  Baseline Follow-Up P-value Baseline Follow-Up P-value 
Medication Use 
ICS 
LTRA 
LABA 
Albuterol 
  
26 (86.7) 
16 (53.3) 
2 (6.7) 
30 (100) 
 
18 (60) 
9 (30) 
3 (10) 
27 (90) 
 
0.008° 
0.016° 
1.00° 
0.25° 
 
12 (63.2) 
8 (42.1) 
1 (5.3) 
19 (100) 
 
9 (47.4) 
4 (21.1) 
1 (5.3) 
18 (95) 
 
0.38° 
0.22° 
1.0° 
1.0° 
Oral Steroid 
Courses 
 0.97 [0-4] 0.47 [0-3] 0.048∞ 0.95 [0-4] 
 
0.21 [0-2] 0.056∞ 
ER Visits  0.67 [0-5] 0.07 [0-5] 0.003∞ 0.53 [0-3] 0 0.04∞ 
Pediatrician 
Visits 
 6.48 [0-30] 2.57 [0-15] 0.001∞ 4.94  [0-17] 0.84 [0-8] <0.001∞ 
 
Table 3C.  Post-operative change medication usage and healthcare utilization in the CT 
Kids Cohort. Medication use and Albuterol expressed as n, all other values represent mean. () 
represents percentage, [ ] represent range. °Sign test, ∞Wilcoxon-Signed Rank Test. 
 
 
 
 
 
 
 
 
	   Koenigs et al. 57 
 
 
 
Table 3D.  Post-operative change medication usage and healthcare utilization in the 
YCAAD Cohort. Medication use and Albuterol expressed as n, all other values represent mean. 
() represents percentage, [ ] represent range. °Sign test, ∞Wilcoxon-Signed Rank Test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	  
  LHW   Overweight  
  Baseline Follow-Up P-value Baseline Follow-Up P-value 
Medication Use 
ICS 
LTRA 
LABA 
  
19(65) 
7 (24) 
5 (17) 
 
12 (41) 
9 (31) 
3(10) 
 
0.016° 
0.50° 
0.50° 
 
10 (55) 
4 (22) 
1 (6) 
 
7 (39) 
3 (17) 
1 (6) 
 
0.25° 
1.00° 
1.00° 
Albuterol Use 
≥3 times per day 
1-2 times per 
day 
2-3 times per 
week 
Once a week or 
less 
Never 
  
4 (14) 
3 (11) 
3 (11) 
5 (19) 
12 (44) 
 
2 (8) 
2 (8) 
1 (4) 
3 (11) 
18 (69) 
0.002°  
1 (6) 
2 (12) 
1 (6) 
8 (47) 
5 (29) 
 
0 
2 (11) 
2 (11) 
5 (22) 
10 (56) 
0.453° 
Oral Steroid 
Courses 
 1.45 [0-8] 0.41 [0-5] 0.014∞ 0.33 [0-4] 0 0.18 
Urgent Care Visits  2.86 [0-50] 1.45 [0-8] 0.12∞ 0.72 [0-6] 0.0 0.18∞ 
ACT Score  18 [7-27] 23 [7-27]  0.001∞ 22 [17-27] 23 [17-27] 0.48∞ 
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Variable + MCID 
n = 34 
- MCID 
n = 40 
P-value 
Age median [range] 5.5 [2-17] 7 [2-14] 0.023° 
Male %(n) 47(16) 73(29) 0.033* 
Latino Ethnicity %(n) 44(15) 45(18) 0.1* 
Race %(n) 
Caucasian 
African American 
Other 
 
77(26) 
14(5) 
9(3) 
 
77(31) 
23 (9) 
0.073≠ 
BMI Percentile 
median [range] 
78 [2-100] 79 [0-100] 0.72° 
Overweight (PAW) %(n) 44(15) 38(15) 0.64* 
Inner City %(n) 33(11) 43(17) 0.47* 
Second Hand Smoke %(n) 21(7) 40(15) 0.13* 
Indication TA %(n) 
SDB/OSA 
RT 
 
76(26) 
24(8) 
 
78(31) 
17(7) 
0.77* 
Asthma Co-Morbidities %(n) 
Chronic Allergies 
Atopy 
Sinusitis 
GERD 
 
68(23) 
76(25) 
47(14) 
33(11) 
 
68(26) 
82(31) 
33(13) 
39(15) 
 
1.00* 
0.57* 
0.46* 
0.81* 
Age Asthma Diagnosis 
median [range] 
2.0 [1-16] 2.0 [1-12] 0.77° 
Age Lung Sx Onset 
median [range] 
1.0 [1-14] 1.0 [1-8] 0.94* 
Asthma Triggers %(n) 
Respiratory Infection 
Seasonal 
Environment 
Home 
Exercise 
Other 
 
88(30) 
62(21) 
41(14) 
32(11) 
56(19) 
3(1) 
 
85(33) 
62(24) 
36(14) 
18(7) 
59(23) 
10(4) 
 
0.74* 
1.00* 
0.81* 
0.18* 
0.82* 
0.36* 
Asthma Limits Activity %(n) 12(4) 13(13) 0.32* 
One year symptom free %(n) 6(2) 23(9) 0.055* 
Controller %(n) 68(23) 32(12) 0.004* 
Mild vs. Mod/Severe  %(n) 35(12) 17.5(7) 0.11* 
History ICU for asthma %(n) 3 (1) 5 (2) 1.00* 
Lifetime Hospitalizations 
median [range] 
0 [0-8] 0 [0-20] 0.46° 
Hospitalized last year %(n) 6(2) 5(2) 1.00° 
Chitinase Activity 3.2 [0.2-35] 3.3 [0.2-21] 0.70° 
YKL-40 34 [13-172] 29 [13-194] 0.37° 
IL-2  8.9 [0-1062] 1.6 [0-253] 0.015° 
IL-4  0.6 [0-6.6] 0.4 [0-2.6] 0.064° 
IL-5   2.4 [0.4-7.8] 1.8 [0-18] 0.24° 
IL-10 12 [0-1918] 5.9 [0-113] 0.33° 
IL-12 16 [0-6787] 7.3 [0-3221] 0.12° 
IL-13  2.4 [0-13] 1.3 [0-23] 0.14° 
IFN-γ  38 [3.3-1014] 25 [0-295] 0.039° 
TNF-α  13 [0-310] 5.3 [0-500] 0.04° 
GM-CSF  29 [0-279] 5.6 [0-91] 0.02° 
 
Table 4. Baseline characteristics that influence if child has clinically significant 
improvement in ACT/TRACK score. All biological data is represented as median [range]. 
Values represent percentage (number). *Fisher’s exact, ≠Pearson’s χ2,  °Mann-Whitney U Test. 
Cytokine levels are in pg/mL, YKL-40 in ng/mL and Chitinase Activity in nMol/mL*hr. 	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Variable Improved 
n = 41 
Not Improved 
n = 59 
P-value  
Age median [range] 5 [2-17] 6 [2-14] 0.28° 
Male %(n) 61(25) 64(38) 0.83* 
Latino Ethnicity %(n) 44(19) 43(25) 0.42* 
Race %(n) 
Caucasian 
African American 
Other 
 
83(34) 
10(4) 
7(3) 
 
73(43) 
22(13) 
9 (3) 
0.26≠ 
BMI Percentile 
median [range] 
73 [2-100] 82 [0-100] 0.91° 
Overweight (PAW) %(n) 42(17) 41(24) 0.97* 
Inner City %(n) 37(15) 26(15) 1.00* 
Second Hand Smoke %(n) 39(15) 26(15) 0.26* 
Indication TA %(n) 
SDB/OSA 
RT 
Other 
 
81(33) 
65(6) 
8(2) 
 
70(41) 
27(16) 
3(2) 
0.15* 
Asthma Co-Morbidities %(n) 
Chronic Allergies 
Atopy 
Sinusitis 
GERD 
 
77(30) 
82(31) 
54(22) 
46(18) 
 
60(35) 
75(43) 
29(17) 
31(18) 
 
0.12* 
0.62* 
0.02* 
0.14* 
Age Asthma Diagnosis 
median [range] 
2.0 [1-16] 2.0 [1-9] 0.08° 
Age Lung Sx Onset°  
median [range] 
1.0 [1-14] 1.0 [1-8] 0.70° 
Asthma Triggers %(n) 
Respiratory Infection 
Seasonal 
Environment 
Home 
Exercise 
Other 
 
83(34) 
59(24) 
39(16) 
15(6) 
71(29) 
20(8) 
 
86(50) 
55(32) 
41(24) 
28(16) 
47(16) 
2(1) 
 
0.78* 
0.84* 
0.84* 
0.15* 
0.023* 
0.003* 
Asthma Limits Activity %(n) 24(10) 17(10) 0.40* 
One year symptom free %(n) 3(1) 23(13) 0.007* 
Controller %(n) 82(32) 34(20) < 0.001* 
Mild vs. Mod/Severe  %(n) 46(19) 17(10) 0.002* 
History ICU for asthma %(n) 7.3(3) 3.4(2) 0.40* 
Lifetime Hospitalizations 
median [range] 
0 [0-35] 0 [0-10] 0.04° 
Hospitalized last year %(n) 20(8) 2(1) 0.003* 
Chitinase Activity 2.6 [0.2-35] 3.4 [0.2-21] 0.09° 
YKL-40 35 [13-172] 30 [13-194] 0.61° 
IL-2  1.2 [0-1062] 2.6 [0-253] 0.73° 
IL-4  0.8 [0-6.6] 0.4 [0-2.7] 0.014° 
IL-5   3.6 [0.4-18] 1.8 [0-32] 0.023° 
IL-10 7.4 [0-1918] 7.7 [0-187] 0.85° 
IL-12 7.3 [0-6787] 9.8 [0-495] 0.80° 
IL-13  3.2 [0-23] 1.4 [0-64] 0.021° 
IFN-γ  36 [0-1014] 28 [2.7-503] 0.43° 
TNF-α  11 [0-310] 6.3 [0-500] 0.33° 
GM-CSF  6 [0-279] 18 [0-1136] 0.17° 
 
Table 5. Baseline characteristics that influence if child has improvement in Urgent Care 
Visits following surgery. All biological data is represented as median [range]. Values represent 
percentage (number). *Fisher’s exact, ≠Pearson’s χ2,  °Mann-Whitney U Test. Cytokine levels are 
in pg/mL, YKL-40 in ng/mL and Chitinase Activity in nMol/mL*hr. 
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Variable Improved 
n = 39 
Not Improved 
n = 60 
P - value  
Age median [range] 5 [2-17] 6 [2-17] 0.16° 
Male %(n) 64 (25) 62 (37) 0.84* 
Latino Ethnicity %(n) 47(17) 45(27) 0.84* 
Race %(n) 
Caucasian 
African American 
Other 
 
82(32) 
8(3) 
10(4) 
 
73(44) 
23(14) 
4(2) 
0.07≠ 
BMI Percentile 
median [range] 
71 [2-100] 86 [0-100] 0.40° 
Overweight (PAW) %(n) 39(15) 43(26) 0.68* 
Inner City %(n) 28(11) 42 (25) 0.20* 
Second Hand Smoke %(n) 37(13) 28(17) 0.49* 
Indication TA %(n) 
SDB/OSA 
RT 
Other 
 
77(30) 
18(7) 
5(2) 
 
72(43) 
25(15) 
3(2) 
0.47* 
Asthma Co-Morbidities %(n) 
Chronic Allergies 
Atopy 
Sinusitis 
GERD 
 
77(28) 
81(29) 
56(22) 
42(16) 
 
63(37) 
76(44) 
28(17) 
32(19) 
 
0.26* 
0.80* 
0.007* 
0.39* 
Age Asthma Diagnosis 
median [range] 
2 [1-12] 2 [1-12] 0.84° 
Age Lung Sx Onset° 
median [range]  
1 [1-5] 1[1-5] 0.60° 
Asthma Triggers %(n) 
Respiratory Infection 
Seasonal 
Environment 
Home 
Exercise 
Other 
 
85(33) 
51(20) 
41(16) 
23(9) 
64(25) 
21(8) 
 
85(51) 
60(36) 
40(24) 
22(13) 
52(42) 
2(1) 
 
1.00* 
0.41* 
1.00* 
1.00* 
0.07* 
0.002* 
Asthma Limits Activity %(n) 31(12) 13(8) 0.043* 
One year symptom free %(n) 8(3) 19(11) 0.24* 
Controller %(n) 84(32) 34(20) < 0.001* 
Mild vs. Mod/Severe  %(n) 62(24) 8(5) <0.001* 
History ICU for asthma %(n) 10.3(4) 2(1) 0.07* 
Lifetime Hospitalizations 
median [range] 
0 [0-35] 0 [0-20] 0.018° 
Hospitalized last year %(n) 21(8) 2(1) 0.002* 
Chitinase Activity 2.9 [0.2-35] 3.3 [0.2-21] 0.58°  
YKL-40 36 [13-172] 31 [13-194] 0.30° 
IL-2  2.0 [0-171] 2.6 [0-1062] 0.97° 
IL-4  0.6 [0-6.6] 0.4 [0-6.6] 0.36° 
IL-5   3.0 [0.4-9] 2.2 [0-32] 0.17° 
IL-10 7.6 [0-108] 7.6 [0-1918] 0.54° 
IL-12 7.0 [0-267] 10 [0-6787] 0.51° 
IL-13  2.3 [0-23] 1.4 [0-64] 0.37° 
IFN-γ  34 [0-704] 30 [0-1014] 0.68° 
TNF-α  11 [0-310] 5.8 [0-500] 0.20° 
GM-CSF  9.3 [0-193] 18 [0-1136] 0.57° 
Table 6. Baseline characteristics that influence if child has clinically significant 
improvement in steroid courses. All biological data is represented as median [range]. Values 
represent percentage (number). *Fisher’s exact, ≠Pearson’s χ2,  °Mann-Whitney U Test. 
Cytokine levels are in pg/mL, YKL-40 in ng/mL and Chitinase Activity in nMol/mL*hr. 	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Variable Improved 
n = 70 
Not Improved 
n = 30 
P - value 
Age median [range] 5 [2-17] 8 [2-14] 0.012° 
Male %(n) 59(41) 73(22) 0.18* 
Latino Ethnicity %(n) 45(30) 47(14) 1.00* 
Race %(n) 
Caucasian 
African American 
Other 
 
79(55) 
13 (9) 
9 (6) 
 
73 (22) 
27 (8) 
0.082≠ 
BMI Percentile 
median [range] 
78.9 [2-100] 63 [0-100] 0.25* 
Overweight (PAW) %(n) 43(30) 37(11) 0.66* 
Inner City %(n) 36(25) 37(11) 1.00* 
Second Hand Smoke %(n) 33(22) 27(8) 0.64* 
Indication TA %(n) 
SDB/OSA 
RT 
Other 
 
77(54) 
20(14) 
3(2) 
 
67(28) 
27(8) 
7(2) 
0.43* 
Asthma Co-Morbidities %(n) 
Chronic Allergies 
Atopy 
Sinusitis 
GERD 
 
74(52) 
79(52) 
44(31) 
40(27) 
 
55(16) 
76(22) 
27(8) 
30(9) 
 
0.16* 
0.79* 
0.12* 
0.50* 
Age Asthma Diagnosis 
median [range] 
2 [1-12] 2 [1-16] 0.69° 
Age Lung Sx Onset° 
median [range]  
1 [1-5] 1 [1-14] 0.98° 
Asthma Triggers %(n) 
Respiratory Infection 
Seasonal 
Environment 
Home 
Exercise 
Other 
 
86(60) 
57(40) 
40(28) 
21(15) 
60(42) 
13(16) 
 
83(24) 
55(16) 
41(12) 
24(7) 
48(14) 
0(0) 
 
0.76* 
1.00* 
1.00* 
0.79* 
0.37* 
0.043* 
Asthma Limits Activity %(n) 23(16) 14(4) 0.18* 
One year symptom free %(n) 6(4) 35(10) 0.001* 
Controller %(n) 68(46) 20(6) < 0.001* 
Mild vs. Mod/Severe  %(n) 39(27) 7(2) 0.001* 
History ICU for asthma %(n) 7(5) 0(0) 0.32* 
Lifetime Hospitalizations 
median [range] 
0 [0-35] 0 [0-10] 0.36° 
Hospitalized last year %(n) 13(9) 0(0) 0.055* 
Chitinase Activity 3.2 [0.2-35] 3.1 [0.2-7.9] 0.25° 
YKL-40 34 [13-172] 30 [13-194] 0.70° 
IL-2  4.1 [0-1062] 1.8 [0-253] 0.17° 
IL-4  0.6 [0-6.6] 0.4 [0-2.6] 0.042° 
IL-5   3.0 [0.4-18] 1.5 [0-32] 0.025° 
IL-10 8.3 [0-1918] 4.5 [0-187] 0.17° 
IL-12 7.4 [0-6787] 8.5 [0-495] 0.50° 
IL-13  2.4 [0-23] 1.0 [0-64] 0.029° 
IFN-γ  36 [0-1014] 25 [2.7-503] 0.16° 
TNF-α  11 [0-310] 4.9 [0-500] 0.041° 
GM-CSF  12 [0-279] 12 [0-1136] 0.88° 
Table 7. Baseline characteristics that influence if child has clinically significant 
improvement in Composite Improvement. All biological data is represented as median [range]. 
Values represent percentage (number). *Fisher’s exact, ≠Pearson’s χ2,  °Mann-Whitney U 
Test. Cytokine levels are in pg/mL, YKL-40 in ng/mL and Chitinase Activity in nMol/mL*hr. 
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FIGURES 	  
	  
 
Figure 1. Children’s asthma improves following TA. P-values represent Wilcoxon Signed-
Rank test A) ACT and TRACK scores rescaled to 25-point scale. B) Number of urgent care visits 
(per year). C) Number of steroid courses (per year). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Serum biomarker levels differ in children with and without asthma prior to TA. P-
values represent Mann-Whitney-U Test. Median bar is displayed with interquartile ranges. Error 
bars represent minimum and maximum values. A) IL-5. B) IL-13. C) Chitinase Activity. 
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Figure 3. Th2 cytokines decrease in children with asthma following TA. P-values represent 
Wilcoxon Signed-Rank Test. Median bar is displayed with interquartile ranges. Error bars 
represent minimum and maximum values. A) IL-4. B) IL-5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Improvement in Asthma Correlates with Decreases in IL-5. Asthma improves 
measured using the composite variable for improvement. P-value represents Mann-Whitney-U.   
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